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 A persisting question in biology concerns the exceptional diversity of metabolic enzymes 
and how they respond to their ligands and dynamic environments with remarkable precision. In 
humans, the family of biotin-dependent carboxylases holds important roles in intermediary 
metabolism. Recent years have witnessed significant progress toward understanding these 
enzymes’ roles in homeostatic regulation. However, due to a lack of structural information, their 
catalytic mechanisms, as well as the macromolecular consequences of their genetic mutations, 
are still not well understood.  
 This dissertation describes the characterization of two biotin-dependent carboxylases that 
catalyze essential metabolic transformations in humans and bacteria, using X-ray crystallography 
to elucidate their structures and biochemical assays to verify their activities. We engineer a novel 
chimeric variant of propionyl-CoA carboxylase (PCC) and produce the first crystal structure of 
its 750-kDa α6β6 holoenzyme. This structure reveals the architecture of PCC’s twelve catalytic 
domains and allows the mapping of its disease-associated gene mutations to predict their effects 
on enzyme stability and catalysis. We also identify and describe a new domain that is integral to 
maintaining inter-subunit contacts within PCC. Following this, we extend our studies to 
methylcrotonyl-CoA carboxylase (MCC), another 750-kDa α6β6 holoenzyme that differs from 
PCC primarily in its substrate preference. The crystal structure of MCC assumes a markedly 
different configuration from PCC despite the high sequence identity between the two. Theorizing 
that these enzymes may represent unique lineages in the evolution of the biotin-dependent 
carboxylases, we apply similar approaches to the study of a third biotin-dependent carboxylase. 
Our efforts have produced the first two holoenzyme structures of CoA-recognizing biotin-
dependent carboxylases, and provide valuable insight for understanding the functions of these 
vital enzymes. 
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Chapter I 
Figure 1. Three classes of biotin-dependent enzymes. Each class of enzymes features a 
translocating biotin/carboxybiotin system that links the activities of the two active sites. Adapted 
from Jitrapakee and Wallace, 2003. 
 
Figure 2. Domain organization of various biotin-dependent carboxylases. Several domains 
are conserved across species, and are colored accordingly. The CT domains of pyruvate 
carboxylase (PC) and urea carboxylase (UC) are distinct from those that recognize acyl-CoA 
substrates. Several species abbreviations are used: Ec (Escherichia coli), Sc (Streptomyces 
coelicolor), Mt (Mycobacterium tuberculosis), Pa (Pseudomonas aeruginosa). The scale bar at 
the bottom indicates the number of amino acids. Adapted from Tong, 2012. 
 
Figure 3. The five biotin-dependent carboxylases found in humans. The sizes of the 
holoenzyme and the structures of their substrates and products are shown. The sites of 
carboxylation are highlighted in red. Note that four of the carboxylases process large acyl-CoA 
substrates, while pyruvate carboxylase (PC) targets a much smaller organic acid.  
 
Figure 4. Cellular localization of human biotin-dependent carboxylases. For clarity, only the 
major metabolic species are shown, and the metabolic pathways are indicated with boxes. The 
dashed lines indicate the direction of cross-membrane transport across the mitochondrial 
membranes. 
 
Figure 5. Crystal structures of prokaryotic and eukaryotic biotin carboxylase. (A) Biotin 
carboxylase from E. coli ACC (EcBC), in complex with ADP, bicarbonate, free biotin, and 
magnesium. (B) Structure of the free-enzyme BC domain from S. cerevisiae ACC. The active 
site is indicated with an asterisk. (C) Detailed view of the EcBC active site. Hydrogen bonding 
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and ion-pair interactions are indicated with dashed lines. Panels A and C are adapted from Chou 
et al., 2009, and Panel B is adapted from Shen et al., 2004. 
 
Figure 6. Proposed mechanism of biotin carboxylation in the BC domain of E. coli ACC. 
The reaction schematic is presented in approximately the same view as the active site in Figure 
5C. Biotin is considered tethered to BCCP, and the orientation of natural ATP substrate shown in 
the mechanism is based on the observed binding mode of ADP. Adapted from Chou et al., 2009 
and based on the mechanism proposed by Knowles, 1989. 
 
Figure 7. Crystal structures of eukaryotic and prokaryotic carboxyltransferase (CT). (A) 
The CT domain from yeast ACC in complex with CoA in one monomer and adenine in another 
monomer (Zhang et al, 2003). (B) The CT domain from Streptomyces coelicolor PCC (ScPCC), 
in complex with biotin and propionyl-CoA (Diacovich et al., 2004). (C) Detailed view of the CT 
active site in ScPCC. The enolate biotin is stabilized by an oxyanion hole (red lines). Green lines 
separate the Cα of propionyl-CoA and N1' of biotin. (D) A separate oxyanion hole stabilizes the 
propionyl enolate.  
 
Figure 8. Proposed mechanism of carboxyl group transfer in the CT subunit of S. coelicolor 
PCC. During the carboxyltransferase reaction, the propionyl and biotin enolates are respectively 
stabilized by the presence of the Gly182/Gly183 and Gly419'/Ala420' oxyanion holes. These 
oxyanion holes are also present in S. coelicolor ACC, and the ' marks indicate residues from a 
different PCCβ protomer. Adapted from Diacovich et al., 2004. 
 
Figure 9. Sequence alignment of the β subunits of  S. coelicolor PCC and ACC. The 
positions of the oxyanion holes are indicated with blue boxes, and the site of the ‘molecular 
switch’ is highlighted in orange.  
 
Figure 10. Crystal structure of the C-terminal region of BCCP from E. coli ACC. (left) The 
C-terminal region consists of eight anti-parallel beta-strands, with the biotinylation motif near 
the middle of the polypeptide sequence. The thumb feature is not present in human ACC. (right) 
  vi 
Detailed view of the biotinylation site and conserved motif. Carboxyl group attachment occurs at 
N1', indicated in red. Adapted from Athappilly and Hendrickson, 1995. 
 
Figure 11.  Two models for biotin translocation in biotin-dependent carboxylases. (a) In the 
‘swinging-arm’ model, biotin translocates between the BC and CT active sites while BCCP 
remains stationary. Adapted from Tong, 2005. (b) In the ‘swinging-domain’ model, BCCP-biotin 
is the mobile unit, as seen in the surface representation of S. aureus pyruvate carboxylase (Xiang 
et al, 2008). The active sites of Monomer 1 BC and Monomer 2 CT are separated by 75 Å.   
 
Figure 12.  Soraphen A inhibits the biotin carboxylase domain of S. aureus ACC. (A) 
Structure of the S. aureus BC domain in complex with soraphen A (green). The active site is 
indicated with an asterisk. (B) Interactions between soraphen and BC. (Zhang et al., 2003) (C) 
The conformation of soraphen within the complex with S. aureus BC; the numbering scheme of 
the macrocyclic ring is indicated. 
 
Figure 13.  Small-molecule inhibitors of the carboxyltransferase domain of ACC. CP-
640186 binds the dimer interface of the CT domain. For the herbicides haloxyfop, tepraloxydim, 





Figure 1.  Propionyl-CoA can be fully oxidized to CO2 through the TCA cycle. The reactions 
linking PCC activity to the TCA cycle are shown on the right. Following PCC activity, the 
methylmalonyl-CoA product undergoes racemization and epimerization before transforming into 
succinyl-CoA, which is a TCA cycle intermediate. These reactions occur within the 
mitochondrial matrix.  
 
Figure 2.  Conserved domains of biotin-dependent carboxylases from bacteria to humans. 
Colors are assigned based on sequence homology. The CT domain of PC is structurally distinct, 
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and is colored accordingly. The same domains are present in each enzyme, although the method 
of assembly presumably varies among different enzymes, forming the basis for structural 
diversity. The scale bar indicates the number of amino acids. Adapted from Tong, 2007. 
 
Figure 3.  Crystal structures of biotin carboxylase (BC), biotin carboxyl carrier protein 
(BCCP), and carboxyltransferase (CT) from E. coli ACC. (A) BC is a dimer, with ADP, 
biotin, HCO3-, and Mg2+ bound in the active site of each monomer (Chou et al, 2009). (B) BCCP 
is biotinylated at a conserved Lys. The thumb feature is absent in human ACC (Athappilly and 
Hendrickson, 1995). (C) CT is a dimer of two stacked monomers, and the CT active sites are 
located at the monomer interface (Bilder et al, 2006). The sequence identities between these 
structures and their HsPCC homologs are (L-R): 49%, 36%, and 27%. 
 
Figure 4. Crystal structures of the acyl-CoA-recognizing subunits of (a) P. shermanii 
transcarboxylase 12S, (b) S. coelicolor PCCβ, and (c) M. tuberculosis AccD5. The subunits 
assemble into a hexamer, and the structures are viewed from the top of each hexamer. Each 
protomer is colored separately.  
 
Figure 5. Synthesis of the bicistronic expression construct used to express PCC 
holoenzymes. (A, B) PCC subunits were individually screened for protein overexpression and 
solubility. (C) PCC holoenzymes were produced by subcloning the PCCα gene and its upstream 
ribosomal binding site into the PCCβ expression plasmid. Although PCCα is not tagged in the 
final construct, the formation of the holoenzyme allows the entire complex to be purified using 
the PCCβ tag, then separated from the PCCβ hexamer based on size. 
 
Figure 6.  Crystals of PCC holoenzymes from H. sapiens, R. pomeroyi, and a R. pomeroyi/R. 
denitrificans chimera. Crystallization conditions are detailed in the Experimental Procedures. 
HsPCC crystals were obtained from a modified coexpression construct that omitted 15 residues 
from the N-terminus of HsPCCβ, while the bacterial crystals contain their respective full-length 
PCCs. The crystals of HsPCC were obtained by Yang Shen. 
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Figure 7.  Structure of the PCC holoenzyme [39]. (A) Looking down the threefold symmetry 
axis of the RpαRdβ chimera of propionyl-CoA carboxylase (PDB code 3N6R). (B) Looking 
down the twofold symmetry axis. The gray envelopes in (C) and (D) are cryo-EM 
reconstructions of human PCC at 15-Å resolution with the crystal structure of the RpαRdβ 
chimera docked into the envelopes, and are viewed in the same orientations as (A) and (B).  
 
Figure 8. Structures of the (a) BT domain from PCC and (b) the PT domain from S. aureus 
pyruvate carboxylase (SaPC). While BT is encoded as a single domain within the primary 
sequence of PCCα, the PT sequence is interrupted by the CT domain of SaPC (see Figure 1) at 
the joint between Helix α1 and the start of the β sheet. 
 
Figure 9. Locations of the active sites and disease-associated gene mutations in the PCC 
holoenzyme. (A) Molecular surface representation of one α subunit and a β2 dimer. The bound 
positions of ADP and bicarbonate in complex with E. coli BC (Chou et al, 2009) and CoA in 
complex with transcarboxylase 12S (Hall et al, 2003) are shown. The BC and CT active sites are 
separated by 55 Å. Domains are colored in the same manner as in Figure 7. (B) Cartoon 
representation of (A), with the locations of propionic acidemia-associated mutations indicated by 
spheres. The position of CoA binding is indicated with the pink molecule. 
 
Figure 10. Effects of propionic acidemia (PA) gene mutations on PCC holoenzyme stability. 
The E. coli cell pellet fraction is indicated with ‘P’ and the soluble supernatant fraction is 
indicated with ‘S’. Three combinations of PA mutations were assessed, and the abbreviations 
are, from left to right: LA+MA (L649A/M640A), LA+LA+MA (L646A/L649A/M650A), and 
RA+RA+LA+MA (R539A/R540A/L649A/M650A). Control lanes of wild-type RpPCC are in 
the lanes labeled ‘PCC’.   
 
Figure 11. The CT active site. (left) Molecular surface representation of the CT binding pocket. 
The modeled binding mode of CoA with the 12S subunit of transcarboxylase is shown. (right) 
Detailed view of the CT active site. Biotinylation occurs on Lys694, which is found within a 
conserved sequence motif (MKM) of BCCP. 
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Figure 12. Schematic illustration of the ATP hydrolysis assay. Because none of the reactants 
or products in the PCC-catalyzed reaction (shown in the purple box) can be tracked 
spetrophotometrically, a coupled-enzyme system featuring pyruvate kinase (PK) and lactate 
dehydrogenase (LDH) links the production of ADP to the disappearance of NADH. The reaction 
is monitored by tracking the decrease in A340 over time. 
 
Figure 13. Illustration of shared sequence identities between the α and β subunits of PCC 
and MCC from humans and Pseudomonas aeruginosa. The sites of carboxylation on 
propionyl-CoA and methylcrotonyl-CoA are indicated with red asterisks. 
 
 
Table 1. Crystallographic data and refinement statistics 
Table 2. Kinetic data for the substrate preferences of wild-type PCC and its mutants 
Table 3. Kinetic data for the substrate preferences of various RpPCC D440 mutants 





Figure 1. Leucine metabolism in humans. A set of six reactions converts L-leucine into either 
energy metabolites (acetoacetate and acetyl-CoA) or mevalonate, which is a steroid precursor. 
The substances indicated in brackets on the right-hand side are metabolites that can accumulate 
when there is a deficiency in the function of their associated enzymes. Such accumulation can 
lead to their toxic buildup and subsequent consequences to human health. Adapted from 
University of Florida, Division of Genetics and Metabolism. 
 
Figure 2. Crystals of the β subunit and holoenzymes of MCC from Pseudomonas 
aeruginosa.  (A) Crystals of full-length MCCβ free enzyme. (B) Crystals of full-length MCC 
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complexed with CoA. (C) Crystals of full-length MCC free enzyme. The crystals in (C) were 
obtained from the same conditions as (B), but required substantially more time to grow. 
 
Figure 3. Crystal structures of the β subunits of P. aeruginosa MCC (left) and Roseobacter 
denitrificans PCC (right). Both subunits assemble as hexamers, and the structures are viewed 
from the top face of each hexamer. The N domain of each β subunit is colored in cyan, and the C 
domain is colored in yellow. The arrows designate the direction (N’C’) of the linker that 
connects the two domains within each enzyme. For clarity, the protomer in the bottom layer 
under each arrow has been omitted from view. 
 
Figure 4.  A flexible 25-residue linker connects the N and C domains of β subunits from 
acyl-CoA carboxylases. Omit Fo-Fc electron density map at 1.5-Å resolution for the domain 
linker of PaMCCβ, contoured at 3σ.  
 
Figure 5.  Sequence alignment of various carboxyltransferase (CT) domains. The sequences 
of β subunits from various acyl-CoA carboxylases and the α subunit of glutaconyl-CoA 
decarboxylase (GCDα), which also recognizes an acyl-CoA substrate, are shown. The linker 
region is not well conserved among the enzymes. 
 
Figure 6. Schematic representations of β2 dimers from MCC (left) and PCC (right). The 
MCC β2 dimer is shown with the bound positions of crotonyl-CoA in complex with the α subunit 
of glutaconyl-CoA decarboxylase (GCDα) (Kress et al, 2009), and the PCC β2 dimer is shown in 
complex with the modeled positions of CoA in complex with transcarboxylase 12S (Hall et al, 
2003). 
 
Figure 7. Structure of the MCC holoenzyme. (A) A view looking down the threefold 
symmetry axis of P. aeruginosa 3-methylcrotonyl-CoA carboxylase. (B) A view looking down 
the twofold symmetry axis. The gray envelopes in (C) and (D) are cryo-EM reconstructions of 
PaMCC contoured at 12-Å resolution, with the crystal structure of the holoenzyme docked 
within, and the views are presented in the same orientations as (A) and (B).  
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Figure 8. CoA binding induces minor conformational changes in the structure of the MCC 
holoenzyme. The holoenzyme structures of the MCC free enzyme (gray) and CoA complex 
(color) are superimposed at the level of the β6 hexamer. Differences in the two structures are 
evident in the positions of the B domain of BC, the α6/α6A helices in the β subunit, as well as 
the absence of BCCP in the free-enzyme structure. 
 
Figure 9. Comparing the MCC and PCC holoenzymes. The crystal structures of the MCC and 
PCC holoenzymes are rendered as molecular surfaces, and equivalent domains are colored in 
similar tones. Only one BCCP was identified in the structure of PaMCC. Although the two 
enzymes are very similar in terms of sequence conservation, domain organization, and function, 
their three-dimensional structures are distinct from each other. 
 
Figure 10. The BT domain. (A) Location of the BT domain within the MCC holoenzyme. The 
sites of four ‘hook’ residues proposed to contribute to holoenzyme integrity are indicated with 
spheres. (B) Schematic representation of the BT domain from MCC. (C) Schematic 
representation of the BT domain from PCC. 
 
Figure 11. Mutations in the BT hook structure can destabilize the MCC holoenzyme. Lane 
headings indicate P for the E. coli cell pellet, S for the supernatant fraction, and E for the eluted 
protein that was isolated using nickel-charged affinity beads. 
 
Figure 12. The BC and CT active sites of MCC. Stereo view of one α subunit and the β6 
hexamer. The BCCP domain (in blue) must translocate a considerable distance to access the two 
active sites. The hexamer is viewed from the side, in the same manner as Figure 6. 
 
Figure 13. The CT active site. (left) The substrate-binding pocket is buried deep in the groove 
formed by the N and C domains of different β subunits. The overlaying portions of the C domain 
are rendered partially transparent to reveal the positions of biotin and 3-methylcrotonyl-CoA 
(MCoA). (right) Detailed view of the CT binding site. Helix α6 is rendered partially transparent 
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to show the MCoA. Although CoA was observed in the MCC holoenzyme structure, the 
additional acyl groups were modeled using the binding mode of crotonyl-CoA in complex with 
GCDα (Kress et al., 2009). 
 
Figure 14. Locations of the BC and CT active sites and disease-associated gene mutations in 
the MCC holoenzyme. (A) Schematic representation of one α subunit and a β2 dimer with the 
bound positions of ADP from E. coli ACC (Chou et al, 2009) and CoA. The locations of 
missense mutations associated with the human disease methylcrotonylglycinuria are indicated 
with spheres. Panels (B) and (C) depict the consequences of the E134K mutation in the BC 
domain, and (D) and (E) indicate likewise for the V375F mutation in the CT domain. 
 
Figure 15. Kinetic assay of wild-type MCC and BCCP eviction mutants. An ATP hydrolysis 
assay was used to compare the catalytic activities of three MCCβ mutants against wild-type 
MCC. Each curve represents the average of three separate trials. The activity of wild-type MCC 
was arbitrarily set to 1.0, and the activities of the mutants are calculated in comparison to this 
value. 
 
Figure 16. Crystals of BCCP eviction mutants from PaMCC. Mutations were introduced in 
the MCCβ subunit, with the intention of destabilizing BCCP-biotin interactions. Crystallization 
conditions are summarized in the Experimental Procedures.  
 
 
Table 1. Crystallographic data and refinement statistics 
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1.1 Introduction to the biotin-dependent carboxylases  
 





Biotin, which is also known as Vitamin H, is a water-soluble vitamin with a backbone 
structure consisting of two fused 5-member rings and an attached valeric acid side chain. Biotin 
is essential to many metabolic processes, including fatty acid biosynthesis and oxidation, aerobic 
respiration, and gluconeogenesis. Although biotin can be synthesized from a pimeloyl-CoA 
precursor in plants, fungi, and bacteria, higher organisms are incapable of this biosynthesis and 
must acquire biotin either through their diets, or through the contributions of their intestinal 
fauna (gut bacteria) [1].  
There are three families of biotin-dependent enzymes (carboxylases, decarboxylases, 
transcarboxylases) and these enzymes are responsible for catalyzing a wide variety of metabolic 
reactions. The biotin-dependent enzymes are noted for their two-part catalytic mechanisms, with 
biotin as a participant in both reactions. In each biotin-dependent enzyme, biotin is incorporated 
as a prosthetic group that is covalently bound to a domain known as the biotin carboxyl carrier 
protein (BCCP; Figure 1). The covalent linkage occurs through the generation of an amide bond 
between the terminal carboxyl group of biotin and the ammonium group of a conserved lysine 
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residue on BCCP. This biotinylated lysine is also referred to as a biocytin group. This addition 
reaction is catalyzed by a biotin protein ligase (BPL), which has both prokaryotic and eukaryotic 
variants [2]. Once the biotin is attached to BCCP, it is considered to sit on a 16-Å ‘swinging arm’ 
that permits the unit to access the dual active sites of the biotin-dependent enzymes (Figure 1). 
However, in at least one enzyme (pyruvate carboxylase), the range of this ‘swinging arm’ is 
insufficient to reach both active sites. As a result, the biocytin group of pyruvate carboxylase is 
considered to be situated on a ‘swinging domain’ of BCCP, where its maximum reach is 




Figure 1. Three classes of biotin-dependent enzymes. Each class of enzymes features a 
translocating biotin/carboxybiotin system that links the activities of the two active sites. Adapted 
from Jitrapakee and Wallace, 2003 [4]. 
 
 The biotin-dependent carboxylases require ATP for their activity, and they catalyze the 
carboxylation of several metabolites associated with carbohydrate, lipid, and protein metabolism. 
The first active site (within the BC domain; Figure 1) catalyzes the carboxylation of biotin, 
which is followed by the resulting carboxybiotin entering the second active site (within the CT 
domain) to transfer its carboxyl group onto the acceptor molecule  [5].  
 The family of biotin-dependent decarboxylases is also known as the sodium ion transport 
decarboxylases, and these enzymes essentially work in the reverse manner as the carboxylases. 
The first active site (on the α subunit) binds the carboxylated CoA molecule, catalyzes its 
decarboxylation, and the carboxybiotin group translocates into the β subunit, where CO2 is 
released from the enzyme. The energy harnessed from decarboxylation is used to pump Na+ 
across the cellular or mitochondrial membrane, after which the resulting electrochemical gradient 
can be used to synthesize ATP for the cell’s energy needs [6].  
 Lastly, the family of transcarboxylases does not incorporate nor release a freely 
carboxylated molecule. The carboxyl group is removed from methylmalonyl-CoA in the first 
(12S) active site and is transferred to pyruvate in the second (5S) active site, generating 
propionyl-CoA and oxaloacetate [7]. Transcarboxylase consists of a central 12S hexameric core, 
which surrounded by twelve 5S subunits and linked by twelve 1.3S subunits (BCCP).  
The focus of this dissertation will be on the family of biotin-dependent carboxylases and 
in particular, the five carboxylases that are found in humans (acetyl-CoA carboxylase isoforms 1 
and 2, propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, and pyruvate carboxylase). 
However, because there is considerable shared sequence and structural homology between the 
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domains of all the biotin-dependent enzymes, we will also make occasional references to 
members of the other families. 
 
1.1.2 Domain organization 
 
All biotin-dependent carboxylases are large macromolecular assemblies that function as 
holoenzymes. The domain arrangements of six unique carboxylases are shown in Figure 2. The 
carboxylases include: acetyl-CoA carboxylase (ACC), propionyl-CoA carboxylase (PCC), 
methylcrotonyl-CoA carboxylase (MCC), pyruvate carboxylase (PC), geranyl-CoA carboxylase 
(GCC), and urea carboxylase (UC). Within this group of enzymes, the ACCs have commanded 
the most scientific attention. While bacterial ACC is assembled from individual subunits, 
mammalian ACC is expressed as a single peptide with multiple domains that assembles into a 
holoenzyme. In humans, ACC is expressed as two tissue-specific isoforms. ACC1 is found in 
lipogenic tissues (e.g., liver and fat) while ACC2 is found in the tissues of oxidative tissues (e.g., 
cardiac and skeletal muscle). 
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Figure 2. Domain organization of various biotin-dependent carboxylases. Several domains are 
conserved across species, and are colored accordingly. The CT domains of pyruvate carboxylase 
(PC) and urea carboxylase (UC) are distinct from those that recognize acyl-CoA substrates. 
Several species abbreviations are used: Ec (Escherichia coli), Sc (Streptomyces coelicolor), Mt 
(Mycobacterium tuberculosis), Pa (Pseudomonas aeruginosa). The scale bar at the bottom 
indicates the number of amino acids. Adapted from Tong, 2012 [8]. 
 
There are three domains found in all biotin-dependent carboxylases: the biotin 
carboxylase (BC) domain and the carboxyltransferase (CT) domain, which contain catalytic 
centers; and the biotin carboxyl carrier protein (BCCP), which ‘shuttles’ reaction intermediates 
between BC and CT by way of its prosthetic biotin group. The CT domains of PC and UC are 
unique from those of ACC/PCC/MCC, which recognize acyl-CoA substrates. This difference 
may have additional implications for the structures of the PC and UC holoenzymes as well. 
 
1.1.3 Human biotin-dependent carboxylases 
 
 
Figure 3. The five biotin-dependent carboxylases found in humans. The sizes of the 
holoenzyme and the structures of their substrates and products are shown. The sites of 
carboxylation are highlighted in red. Note that four of the carboxylases process large acyl-CoA 
substrates, while pyruvate carboxylase (PC) targets a much smaller organic acid.  
 
 
 ACC1 and ACC2 carboxylate the α-carbon of acetyl-CoA and generate malonyl-CoA as 
a product. The most basic ACC assembly (the full-length polypeptide) is ~250 kDa in size, 
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although studies of ACCs from wheat grass and rats have indicated that dimerization is required 
for ACC activity [9, 10]. PCC also targets the α-carbon of its saturated acyl-CoA substrate, 
propionyl-CoA, and the carboxylated product is known as methylmalonyl-CoA. Methylcrotonyl-
CoA carboxylase accepts an α-β unsaturated acyl ester, and carboxylates the γ-carbon to produce 
methylglutaconyl-CoA. Both the holoenzymes of PCC and MCC are large assemblies of 
approximately 750 kDa in size. Finally, PC catalyzes the carboxylation of pyruvate to form 
oxaloacetate, and its holoenzyme assembles a 500 kDa tetramer.  
 
 
1.2 Biological roles: essential metabolic enzymes 
 
1.2.1 Tissue/Cellular Localization 
 
In humans, the biotin-dependent carboxylases are widely expressed throughout the body, 
but are the most active in the tissues and organs involved in energy metabolism. Such organs 
include those of the digestive tract, liver, and adipose tissue [11, 12]. Of the two ACC isoforms, 
ACC1 contributes to fatty acid biosynthesis, and is accordingly expressed in lipogenic tissues 
such as the liver and adipose fat [13]. In contrast, ACC2 mediates fatty acid oxidation and is 
primarily found in oxidative tissues with high energy demands, such as the liver, heart, and 
skeletal muscle. Although the liver contains both ACC isozymes, the cellular 
compartmentalization of malonyl-CoA (either within the cytosol or at the mitochondrial surface) 
ensures a specific cellular response [14]. Interestingly, ACC1 has been implicated in ensuring the 
survival of breast cancer cells in vitro. The siRNA-mediated silencing of ACC1 in tandem with 
fatty acid synthase (FAS) genes resulted in a decline in fatty acid synthesis, an arrest in cell 
proliferation, and the induction of apoptotic pathways within the cancer cells.  [15]. Therefore, 
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ACCs and other components of the lipogenic pathway may serve as possible targets for anti-
cancer treatments. 
In addition to somatic tissues, the biotin-dependent carboxylases of commensal gut 
bacteria also provide a significant source of carboxylase activity and consequently, carboxylation 
products. This proves problematic for individuals with propionic acidemia (PCC deficiency), as 
they are unable to process the short-chain fatty acids and propionic acid secreted by their 
intestinal fauna. As a result, patients with propionic acidemia are typically put on metronidazole 
and/or clindamycin regimens to reduce their numbers of endogenous gut bacteria, and in turn, 
their propionate load [16, 17]. 
 
Figure 4. Cellular localization of human biotin-dependent carboxylases. For clarity, only the 
major metabolic species are shown, and the metabolic pathways are indicated with boxes. The 




 The primary activities and cellular locations of the human biotin-dependent carboxylases 
are shown in Figure 4. Of the five carboxylases, PCC, MCC, and PC are active within the 
mitochondrial matrix. Each enzyme is initially synthesized in the cytoplasm with an N-terminal 
leader peptide that directs their migration to the outer mitochondrial membrane [18-20], and 
these peptides are proteolytically cleaved during the migration process. At the mitochondrial 
surface, the enzymes are imported into the organelle in a membrane-potential-dependent manner 
[19]. In contrast, both ACC isoforms exist as cytoplasmic proteins. ACC1 floats freely in the 
cytosol, while ACC2 is tethered to the outer mitochondrial membrane, facing the cytoplasm. 
 
1.2.2 Roles in nutrition and energy metabolism 
 
The various substrates of the human biotin-dependent carboxylases are shown in Figure 
3, and comprise major metabolites and nutrients that can be found within the human diet. Acetyl-
CoA is a key energy ‘currency’ within the cell, and is produced from the metabolism of all three 
nutrient groups (lipids, carbohydrates, proteins) primarily through cellular respiration and β-
oxidation of fatty acids [21]. Propionyl-CoA is the three-carbon analog of acetyl-CoA, and is 
also produced from the β-oxidation process. Fatty acids containing an odd number of carbon 
atoms undergo initial rounds of β-oxidation to remove two-carbon units of acetyl-CoA, until 
only propionyl-CoA remains. A major source of propionyl-CoA is from the metabolism of 
several amino acids (Val, Thr, Ile, and Met) as well as cholesterol. Methylcrotonyl-CoA is a 
product of leucine metabolism. Pyruvate is unlike the other substrates in that it is a small organic 
acid, lacks the CoA group, and is a major metabolite in several different cellular pathways. The 
major source of cellular pyruvate results from glycolysis (which produces pyruvate as the end 
product), although the catabolism of glucogenic amino acids (Ala, Cys, Gly, Ser, Thr) can also 
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generate pyruvate [22]. Metabolism of cellular pyruvate is achieved through the actions of 
gluconeogenesis, aerobic/anaerobic respiration, and pyruvate carboxylase (PC). 
The compartmentalization of these enzymes within the cell ensures a coordinated and 
robust response to environmental perturbations. For example, following a large meal, the 
digested lipids, carbohydrates, and proteins are broken down into TCA cycle intermediates, such 
as acetyl-CoA. In resting cells, the majority of acetyl-CoA is directed toward fatty acid 
biosynthesis for long-term energy storage. Because this process takes place in the cytosol, and 
acetyl-CoA cannot directly pass through the mitochondrial membrane, it is combined with 
oxaloacetate to form citrate (citrate synthase). Citrate crosses the membrane through the citrate 
transporter, and is subsequently converted back into oxaloacetate and acetyl-CoA (citrate lyase) 
[23]. At this point, acetyl-CoA can enter either the lipogenic or oxidative (energy-producing) 
pathways, depending on the cell’s particular energy requirements. When the cell undergoes 
significant stress and increases its energy demands, the stored energy (in the form of 
triglycerides) is processed through the fatty acid oxidation pathway and in the mitochondria, 
where it is released from the TCA cycle in the form of ATP.   
The excess cytosolic oxaloacetate, which results from its mitochondrial co-export with 
acetyl-CoA, needs to be re-imported into the mitochondria to maintain a balanced supply of 
oxaloacetate across the mitochondrial membrane. In the cytopsol, oxaloacetate is first reduced to 
malate (malate dehydrogenase), and malate is subsequently oxidized to pyruvate (malic enzyme). 
Pyruvate crosses the membrane through the pyruvate transporter [24]. Once inside the matrix, 
the actions of pyruvate carboxylase convert pyruvate back to oxaloacetate, and this species can 
either enter the TCA cycle for full oxidation to CO2, or combine with acetyl-CoA to restart the 
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lipogenic or oxidative pathways. Alternatively, pyruvate can be directly transformed into acetyl-
CoA through the pyruvate dehydrogenase complex.  
 
1.3 Catalytic components 
 
Although the existence of the BC and CT reactions has long been known, the finer details 
of biotin translocation between the BC/CT active sites is still a topic of current research. From a 
structural perspective, the biotin-carboxylases are remarkably challenging targets. The smallest 
of the holoenzyme complexes is 500 kDa in size (pyruvate carboxylase), but higher-order 
oligomers of more than 1 MDa have been reported for mammalian ACCs when bound to the 22-
kDa cytosolic protein MIG12 [25]. As such, the elucidation of these holoenzyme structures 
through classical techniques such as X-ray crystallography and NMR was considered to be an 
ambitious goal. One modified approach is to first determine the structures of individual domains, 
and then compile the structural information into a low-resolution electron microscopy (EM) 
reconstruction of the holoenzyme. The initial studies from this ‘divide and conquer’ approach are 
presented in the following sections. 
 
1.3.1 The biotin carboxylase domain 
Biotin carboxylase (BC) is a 48-kDa enzyme that catalyzes the ATP-dependent 
carboxylation of biotin to form carboxybiotin and ADP. The BC domain exists as a monomer in 
yeast (Saccharomyces cerevisiae) and as a 96-kDa homodimer in E. coli, although this dimer 
interface can be disrupted to yield monomeric mutants that still retain some activity in vitro [26].  
The primary sequences of BC domains from various species are highly conserved. The 
BC domain of yeast (570 residues) shares 65% sequence identity with the BC domain of human 
ACC1 (543 residues), while the sequence identity of yeast BC with E. coli BC (449 residues) is 
 11 
slightly lower, at 36%. Generally, there is higher sequence conservation among eukaryotic BCs 
and among prokaryotic BCs, rather than between eukaryotes and prokaryotes. This discrepancy 
between eukaryotic and prokaryotic BCs is also thought to result in distinct differences in their 
three-dimensional structures. 
The first crystal structure of biotin carboxylase was determined in 1994 from E. coli [27] 
and was found to feature three distinct domains surrounding a nucleotide-binding site. BC was 
eventually identified as a member of the ATP-grasp family of enzymes, which primarily catalyze 
the ATP-dependent conjugation of an amino or thiol group to a carboxylated entity [28, 29]. 
Family members share a similar overall fold consisting of the A, B, and C sub-domains, and 
ATP is ‘grasped’ by the A and C domains. In the structure of E. coli BC free enzyme, the B 
domain assumes an open/extended conformation away from the nucleotide-binding site, and 
forms a closed lid upon ATP binding. Interestingly, the B-domain of yeast BC maintains a closed 
conformation, even in the absence of ATP [30].  
A search of the Protein Data Base (PDB) reveals that many crystal structures of BC have 
been determined, from all three branches of life (archaea, bacteria, eukarya). A number of these 
structures are in complexes with ligands, activators, or inhibitors, and have provided valuable 






Figure 5. Crystal structures of prokaryotic and eukaryotic biotin carboxylase. (A) Biotin 
carboxylase from E. coli ACC (EcBC), in complex with ADP, bicarbonate, free biotin, and 
magnesium. (B) Structure of the free-enzyme BC domain from S. cerevisiae ACC. The active site 
is indicated with an asterisk. (C) Detailed view of the EcBC active site. Hydrogen bonding and 
ion-pair interactions are indicated with dashed lines. Panels A and C are adapted from Chou et al., 
2009 [31] and Panel B is adapted from Shen et al., 2004 [32]. 
 
E. coli BC (EcBC) forms a homodimer with twofold symmetry, and binding of the ADP 
nucleotide induces the closed conformation of the B domain (Figure 5A). In comparison, the 
structure of the BC domain from yeast ACC is a monomer and is shown in Figure 5B. As noted 
previously, its B domain also maintains a closed conformation over the BC active site, even 
though ATP is not present.  
One explanation for the incongruity in sequence conservation among eukaryotic and 
prokaryotic BCs is a difference in size; namely, eukaryotic BCs are generally larger than their 
bacterial counterparts. This phenomenon owes itself to the presence of an elongated A-B domain 
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linker in eukaryotic BCs, as well as additional insertions within the first two helices of the A 
domain (Figure 5B) [8, 30].  
The structure of EcBC in complex with ADP, bicarbonate, biotin, and magnesium is 
shown in Figure 5A, and provides valuable information regarding how substrates are recognized 
within the BC active site. Both ADP and bicarbonate are recognized by a network of interactions 
formed by the side chains and peptide backbones of nearby residues. Of note, the N1' atom (the 
site of carboxyl group attachment; see Figure 5) of biotin is located 2.7 Å from bicarbonate, and 
appears to be poised for catalysis. The divalent magnesium ion is octahedrally coordinated by 
ADP, Glu276, Glu288, and two water molecules.  
It should be noted that, in order to ensure ligand incorporation, the concentrations of the 
BC ligands in the crystallization conditions are significantly higher than their typical intracellular 
levels. In addition, the exogenous biotin is not tethered to BCCP as it is found in nature, and thus 
its binding mode may be slightly different within the context of the ACC holoenzyme. 
Nevertheless, all the ligands were identified with clearly defined electron density at 2.0-Å 
resolution, and the observations made within this structure supported the proposal of a 




Figure 6. Proposed mechanism of biotin carboxylation in the BC domain of E. coli ACC. The 
reaction schematic is presented in approximately the same view as the active site in Figure 5C. 
Biotin is considered tethered to BCCP, and the orientation of natural ATP substrate shown in the 
mechanism is based on the observed binding mode of ADP. Adapted from Chou et al., 2009 [31] 
and based on the mechanism proposed by Knowles, 1989 [5]. 
 
 In the proposed mechanism for biotin carboxylation, Glu296 is identified as the general 
base that initiates catalysis, and its nucleophilicity is likely enhanced by the adjacent Glu211. 
Although the standard pKa of a bicarbonate ion is defined as 10.3, it is thought that the acidic 
residues in the local environment will lower the pKa and permit its deprotonation. Upon 
abstraction of the bicarbonate hydrogen, a carboxyphosphate intermediate is formed, and 
subsequently decomposes into Pi and CO2. The resulting inorganic phosphate extracts a proton 
from the N1' atom of biotin, resulting in a biotin enolate that is stabilized by the guanidinium 
group of Arg338. Lastly, the tautomerization of the biotin enolate into the keto form results in 
the formation of carboxybiotin, which is a product of the BC reaction. All the key residues 
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implicated in this mechanism are well conserved among BCs of different species, which likely 
supports their roles in BC catalysis.  
 
1.3.2 The carboxyltransferase domain 
In biotin-dependent carboxylases, the carboxyltransferase (CT) domain catalyzes the 
carboxylation of the holoenzyme’s namesake substrate. Carboxybiotin serves as the carboxyl 
source and is produced in the preceding BC reaction, whereas the biotin scaffold is permanently 
tethered to the biotin carboxyl carrier protein (BCCP). The CT reaction does not require 
additional energy input to proceed. Because the CT domain alone recognizes the carboxylation 
targets, the CTs that target acyl-CoA substrates are very different than the those that recognize 
keto acids (such as pyruvate) and carbamides [33]. This dissertation focuses on the enzymes that 
target acyl-CoA substrates, and all subsequent mentions of CT domains refer to the acyl-CoA 
enzymes unless otherwise specified.  
The primary sequences of CTs from eukaryotic, multi-domain ACCs are highly 
conserved, but share limited sequence homology with those of prokaryotic, multi-subunit ACCs 
[4]. This difference is manifested in the unique organization of the eukaryotic and prokaryotic 
enzymes: eukaryotic CTs consist of two sub-domains (N- and C-terminal domains), while 
bacterial CTs are assembled from two subunits (α and β). There are no close homologs of CT 
apart from enzymes associated with acyl-CoA thioester modifications [34], which include the 
biotin-dependent carboxylases.  
The first high-resolution structures of CT were obtained in 2003, featuring the 90-kDa 
free enzyme from Saccharomyces cerevisiae at 2.5-Å resolution and a CoA-bound complex at 
2.7-Å resolution [35]. Yeast CT was observed to form a stable homodimer, and the dimer 
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interface consists of residues that are highly conserved with the CT domains of other ACCs. 
Each CT protomer contains an internal crotonase fold, which consists of two perpendicular beta-
sheets linked by alpha-helices (β-β-α superhelix) [36, 37]. The crotonase motif is only present in 
the CT domains that accept acyl-CoA substrates. 
In the structure of yeast CT, the substrate-binding site was identified at the dimer 
interface, in a deep groove formed by the N domain from one protomer and the C domain from 
another protomer. As a consequence, dimerization is required to form the CT active site, and in 
turn, permit catalysis.  
In 2004, the structure of the CT subunit from the bacterium Streptomyces coelicolor was 
reported, and was found to possess many of the same features as its yeast equivalent. One 
significant difference, however, was that its CT subunits assembled as a ring-shaped hexamer, or 
a trimer of dimers [38]. This hexameric arrangement has also been witnessed in the CT domains 
of several bacterial enzymes, including the α subunit of glutaconyl-CoA decarboxylase [39, 40] 
and the 12S subunit of transcarboxylase [41]. The structure of S. coelicolor CT was also obtained 
in complex with several ligands, lending insight into its catalytic activities. Both the structures of 





Figure 7. Crystal structures of eukaryotic and prokaryotic carboxyltransferase (CT). (A) 
The CT domain from yeast ACC in complex with CoA in one monomer and adenine in another 
monomer [35]. (B) The CT domain from Streptomyces coelicolor PCC (ScPCC), in complex with 
biotin and propionyl-CoA [38]. (C) Detailed view of the CT active site in ScPCC. The enolate 
biotin is stabilized by an oxyanion hole (red lines). Green lines separate the Cα of propionyl-CoA 
and N1' of biotin. (D) A separate oxyanion hole stabilizes the propionyl enolate.  
 
Diacovich et al. determined the structure of the CT subunit from S. coelicolor PCC in 
complex with biotin and propionyl-CoA, and identified two oxyanion holes (G182/G183 from 
one β protomer and G419'/A420' from another β protomer) that could be used to stabilize 
reaction intermediates. In addition, the bound positions of the ligands revealed that the ureido 
(N1') nitrogen of biotin was appropriately located with respect to the alpha-carbon of propionyl-
CoA, thereby facilitating the latter’s deprotonation and subsequent enolization. 
However, it was not clear which species initiated the carboxyltransfer reaction. Early 
studies of the CT from E. coli ACC suggested that the overall reaction proceeded in a stepwise 
manner. A series of sulfhydryl-modifying experiments implicated a cysteine residue as the 
initiating nucleophile [5, 42]. However, an active site cysteine was not found in the structure of 
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the CT domain from yeast ACC. Moreover, mutations in the vicinity of the active site failed to 
identify a residue that that was absolutely essential for catalysis. Therefore, the CT mechanism 
likely features biotin as the active site base – or more specifically, its deprotonated ureido 
nitrogen [5, 35]. Based on these observations, a detailed mechanism for the CT reaction was 
described for S. coelicolor PCC [38] (Figure 8). 
 
 
Figure 8. Proposed mechanism of carboxyl group transfer in the CT subunit of S. coelicolor 
PCC. During the carboxyltransferase reaction, the propionyl and biotin enolates are respectively 
stabilized by the presence of the Gly182/Gly183 and Gly419'/Ala420' oxyanion holes. These 
oxyanion holes are also present in S. coelicolor ACC, and the ' marks indicate residues from a 
different PCCβ protomer. Adapted from Diacovich et al., 2004 [38]. 
 
 
The proposed mechanism for the CT reaction begins with a conformational change within 
the enzyme, which bends the planar CO2-N1'-CO-NH orbitals to destabilize the carboxyl-biotin 
linkage and liberate CO2. The resulting biotin enolate is stabilized within the G419'/A420' 
oxyanion hole before tautomerizing with its keto form, and the ureido nitrogen subsequently 
abstracts the Cα proton from propionyl-CoA. Biotin is regenerated in this process. The propionyl 
enolate is stabilized by G182/G183, and its ensuing attack on CO2 produces methylmalonyl-
CoA, which is the overall product of the PCC reaction.  
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The sequence alignments of various CTs, including S. coelicolor ACC as well as the 
PCCs and ACCs from other organisms, indicate that the G182/G183 and G419'/A420' residue 
pairs are highly conserved. This suggests that the oxyanion holes are involved in a common 
catalytic scheme, and emphasizes the usefulness of studying homologous enzymes to better 
understand the catalytic properties of the entire family of biotin-dependent carboxylases.  
One caveat of the mechanism is that the protein-ligand interactions observed in the 
crystal structure are those of bound propionyl-CoA and biotin, which do not form a productive 
substrate pair (unlike carboxybiotin/propionyl-CoA or biotin/methylmalonyl-CoA, the latter pair 
being products of the PCC reaction). However, the location and orientation of the oxyanion holes 
provide convincing arguments for the proposed catalytic scheme.  
Diacovich et al. also used the crystal structure of S. coelicolor PCCβ to generate a 
homology model of ACCβ from the same organism. In the process, it was discovered that, with 
the exception of a single amino acid, nearly every other active site residue was conserved 
between the two enzymes. This suggested that the recognition of unique acyl group 
functionalities within the CT domain is limited to a very small subset of amino acids. The variant 
amino acid was found at position 420 in ACCβ (Ile420) and position 422 in PCCβ (Asp422; see 
Figure 9). When these residues were exchanged between the enzymes, by generating an I420D 
mutant in ACC and a D422I mutant in PCC, it was found that the substrate specificity was 
interconverted as well. In other words, ACCβ-I420D exhibited a preference for propionyl-CoA 
as a substrate, whereas PCCβ-D422I preferred acetyl-CoA. This ‘molecular switch’ represents a 
potential control mechanism for determining catalytic activity in these enzymes, and may be of 
interest for disease therapies as well. It remains to be seen, however, whether this switch is 
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present in other biotin-family enzymes as well, and additional structural information is needed to 
understand its mode of action.  
 
Figure 9. Sequence alignment of the β subunits of  S. coelicolor PCC and ACC. The positions 
of the oxyanion holes are indicated with blue boxes, and the site of the ‘molecular switch’ is 
highlighted in orange.  
 
 
1.3.3 The biotin carboxyl carrier protein  
 
In biotin-dependent carboxylases, the BC and CT activities are linked by a 
carboxybiotin/biotin shuttle, which is covalently tethered to the biotin carboxyl carrier protein 
(BCCP) at the site of a conserved lysine residue and motif (MKM) [43, 44]. The addition of 
biotin to BCCP is catalyzed by biotin protein ligase (BPL), which is known as BirA in 
prokaryotes and as holocarboxylase synthase (HCS) in eukaryotes. This process is remarkably 
specific, and can target a specific MKM lysine for modification even while tolerating variations 
in the motif’s flanking sequences [45]. 
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While BirA and HCS both share biotin ligase activities, they are not exact orthologs of 
each other. The length of BirA is 325 residues, while HCS features a DNA-binding domain in its 
N-terminal half and contains 726 residues in total [46]. The sequence identity of their 
biotinylation domains is much more similar, and the ~130 amino acids comprising this common 
region share 60% sequence identity. Both BirA and HCS execute their biotinylation activities in 
two steps: an addition of ATP to free biotin to form the intermeidate biotinyl-5’-AMP, followed 
by the transfer of the biotin group to the target protein [47, 48]. 
An insufficiency in HCS activity in humans leads to holocarboxylase synthetase 
deficiency, which affects all biotin-dependent enzymes in the body. As a result, affected patients 
may experience stunted growth and immunodeficiencies [49]. In addition, because HCS is 
involved in biotinylating several metabolic targets, the levels of biotinylated histone proteins are 
also reduced as well [50].  
E. coli BCCP exists as a single polypeptide and consists of an N-terminal and C-terminal 
domain. Although BCCP had been isolated in multiple active forms, ranging in size from 45 kDa 
to 9 kDa, early biochemical techniques occasionally resulted in inadvertent cleavage between the 
domains, complicating the subsequent data analysis [51]. In 1995, Athappilly and Hendrickson 
purified recombinant BCCP and treated the product with subtilisin Carlsberg to isolate the 9-kDa 
C-terminal region, the structure of which is shown:  
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Figure 10. Crystal structure of the C-terminal region of BCCP from E. coli ACC [52]. (left) 
The C-terminal region consists of eight anti-parallel beta-strands, with the biotinylation motif near 
the middle of the polypeptide sequence. The thumb feature is not present in human ACC. (right) 
Detailed view of the biotinylation site and conserved motif. Carboxyl group attachment occurs at 
N1', indicated in red.  
 
The structure of the 9-kDa C-terminal region of E. coli BCCP is essentially divided into 
two halves, and each half consists of four anti-parallel beta-strands (respectively numbered β1-β4 
and β5-β8) [52]. The biotinylation site is located at the distal end of a hairpin turn between β4 
and β5. The internal residues of BCCP are largely hydrophobic and help to maintain the 
domain’s stability through hydrophobic and van der Waals interactions. These forces are thought 
to aid in maintaining BCCP’s conformation during catalysis, when the carboxybiotin/biotin 
system translocates repeatedly between the BC and CT domains.  
E. coli BCCP was also found to possess a ‘protruding thumb’ within its C-terminal 
region, and this ‘thumb’ interacts with the covalently bound biotin. This feature is not present in 
human BCCP, and consequently, its bound biotin is more flexible than that of E. coli [53]. More 
impressively, the ‘thumb’ prevents the human biotin ligase (HCS) from accessing the 
biotinylation site within BCCP, whereas the bacterial BirA does not experience such interference 
[54]. This distinction in enzyme-ligand interactions is likely an indication of divergent evolution 
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in the eukaryotic and prokaryotic biotin-dependent carboxylases over time, and may be an 
important factor in the development of antibiotics against pathogenic bacteria. 
In addition to enzymatic biotinylation, biotin protein ligases have also been shown to 
possess transcription repressor activity [55, 56]. A recent structural study revealed that 
Staphyloccoccus aureus BPL dimerizes upon binding biotin, and the resulting complex is 
capable of binding a 44-bp fragment of the bioO operon, which controls biotin biosynthesis [57]. 
Interestingly, the presence of BCCP dissolves the BPL dimer, even in the presence of excess 
biotin. These findings demonstrate that BCCP is involved in both catalytic and regulatory 
activities, and provide the first structural data for the DNA-binding family of biotin protein 
ligases.  
 
1.4 A common mechanism and a translocating factor 
 
 The defining attribute of the biotin-dependent carboxylases is the presence of two 
catalytic activities, linked by the transfer of carboxybiotin/biotin. Although the structures of BC, 
CT, and BCCP yielded considerable insight into their catalytic potential, there remained many 
unanswered questions regarding the holoenzymes’ overall mechanism. Specifically, very little 
was known regarding the mode of biotin/carboxybiotin exchange between the BC and CT 
domains. In addition, several carboxylases were known to comprise higher-order oligomers (α4β4 
for PC; α6β6 for PCC and MCC), but it was not certain whether the protomers functioned as 
independent units, or if they engaged in coordinated catalysis.  
 The earliest descriptions of biotin-dependent carboxylation gave rise to the ‘swinging-
arm’ model for translocation, in which biotin oscillates between the BC and CT active sites 
(Figure 11A) [5, 58]. This model was supported by studies of the 1.3S subunit (BCCP) from 
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Propionibacterium shermanii transcarboxylase, which employed NMR techniques to study the 
flexibility of the biocytin group [59]. The maximum reach of such a biotin moiety spans 
approximately 16 Å, which is more than sufficient to cover the 7 Å between the two active sites 
of P. shermanii transcarboxylase [60, 61].  
 
 
Figure 11.  Two models for biotin translocation in biotin-dependent carboxylases. (a) In the 
‘swinging-arm’ model, biotin translocates between the BC and CT active sites while BCCP 
remains stationary. Adapted from Tong, 2005 [62]. (b) In the ‘swinging-domain’ model, BCCP-
biotin is the mobile unit, as seen in the surface representation of S. aureus pyruvate carboxylase 
[3]. The active sites of Monomer 1 BC and Monomer 2 CT are separated by 75 Å.   
 
The biotin ‘swinging-arm’ was considered the predominant model for translocation until 
the crystal structures of Rhizobium etli and Staphylococcus aureus pyruvate carboxylase (PC) 
were determined. These structures revealed that the BC and CT active sites are separated by 75 
Å [3, 63], which is far beyond the range of a fully extended biotin and therefore eliminates the 
possibility of a biotin swinging-arm for PC catalysis. As a result, a ‘swinging-domain’ model for 
BCCP-mediated translocation was proposed. Although the swinging-domain model is strongly 
supported by the structure of PC, it was uncertain whether the other biotin-dependent 
carboxylases will also exhibit this feature. Pyruvate is a small organic molecule, and 
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ACC/PCC/MCC target larger acyl-CoA substrates. In addition, the sequences of the CT domains 
are vastly different between PC and the acyl-CoA carboxylases. 
In addition to pioneering the concept of the swinging domain, the crystal structures of PC 
revealed that one round of catalysis requires the contribution of two different monomers. In 
Figure 11, the BCCP of Monomer 1 is shown interacting with the CT domain of Monomer 2. 
This structure provided the first evidence that a biotin-dependent carboxylase could employ 
different protomers for a single round of catalysis. One implication of such inter-domain 
coordination is the possibility of allosteric regulation as a control mechanism [64, 65]. However, 
the relevance of PC’s structure for other biotin-dependent carboxylases may be limited due to its 
unique CT domain. Therefore, a crystal structure of a biotin-dependent acyl-CoA carboxylase is 
of significant importance. 
 
1.5 Potential drug discovery targets 
 
The family of biotin-dependent carboxylases holds many important roles in metabolism 
and homeostatic regulation, across all walks of life. As such, these enzymes are promising drug 
targets, and the ability to modulate their expression and activities may hold the key to controlling 
a number of human diseases, including cancer, diabetes, and pathogenic infections. One 
particularly enticing target is ACC2, which inhibits fatty acid oxidation in humans (Figure 4). By 
blocking the activities of ACC2, it is possible to drive continuous fatty acid oxidation. Mice 
deficient in ACC2 exhibit increased feeding tendencies (hyperphagy) compared to their wild-
type counterparts, but display lower body weights [66, 67]. If an inhibitor of human ACC2 is 
developed and brought to market, it could dramatically enhance the lifestyles of many 
individuals, particularly those residing in first-world countries and indulging in sedentary habits. 
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In the past decade, several small molecules have been identified and shown to selectively 
inhibit the BC and CT domains in a species- and enzyme-specific manner. The differences 
between these enzymatic orthologs constitute the basis of structure-based drug design for this 
family of enzymes. While the sequences and structures may be similar across different species, 
their minute variations are more than sufficient to permit the fine-tuning of an inhibitor’s affinity 
and specificity to target a single enzyme with extreme accuracy. Several examples of specific 
inhibitors, targeting the BC and CT domains, are discussed in the following sections. 
 
1.5.1 Soraphen A: an inhibitor of biotin carboxylase 
 
Soraphen A is a polyketide natural product that possesses strong fungicide activity and 
has also been shown to be a highly specific and potent (nanomolar) inhibitor of eukaryotic BCs 
[68] while exhibiting no effect on bacterial BC [69]. Although the compound was isolated in the 
early 1990s and its inhibitory activities toward various pathogenic fungal ACCs were well 
documented [70, 71], it was not until 2003 that a structure of soraphen A, in complex with its 




Figure 12.  Soraphen A inhibits the biotin carboxylase domain of S. aureus ACC. (A) 
Structure of the S. aureus BC domain in complex with soraphen A (green). The active site is 
indicated with an asterisk. (B) Interactions between soraphen and BC. [35] (C) The conformation 




The crystal structure of soraphen A in complex with the BC domain of S. aureus ACC 
revealed that soraphen is an allosteric inhibitor, and binds approximately 25 Å from the active 
site, at the interface of the A and C domains (Figure 12A) [35]. There are multiple hydrogen-
bonding contacts and van der Waals interactions between the inhibitor and the BC domain, 
which explains its high binding affinity (Figure 12B). These residues are highly conserved 
among eukaryotic BCs, and may explain how soraphen is able to preferentially target these BCs 
over their prokaryotic counterparts. A mutation at any one of these conserved residues has 
immediate effects on soraphen affinity; in yeast, the K73R mutation confers resistance to the 
compound [72], while the S77Y mutation is thought to generate steric clashes between the 
compound and the tyrosine side chain, thereby compromising binding [70]. The high specificity 
of soraphen for eukaryotic BC domains can also be explained by the architecture of the 
prokaryotic BC subunit. The structure of E. coli BC reveals a 3-Å shift in the position of β19 at 
the predicted soraphen-binding site; this shift directly clashes with the predicted binding position 
of soraphen. This finding, coupled with additional rearrangements in the orientation of nearby 
amino acid side chains, essentially excludes soraphen from binding prokaryotic BC domains. In 
spite of this wealth of structural and biochemical data, however, the method through which 
soraphen exerts its inhibitory effects is still not clear.  
While soraphen A is still the best-characterized BC inhibitor to date, two recent studies 
from Pfizer have capitalized on advanced screening techniques to identity new candidate 
inhibitors against bacterial BC subunits.  In the first study, Miller et al. employed whole-cell 
screening to identify a set of antibacterial pyridopyrimidines, and demonstrated their inhibition 
against Haemophilus influenzae BC using in vitro and in vivo models [73]. A second study by 
Mochalkin et al. used fragment-based screening to assemble a collection of ‘building blocks’. 
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Successive rounds of optimization produced a series of amino-oxazole compounds, and their 
antibacterial properties were subsequently demonstrated with ACC activity assays and structural 
data [74]. These new approaches for drug discovery have significant advantages over the 
classical methods of compound screening, and will likely increase in popularity in the coming 
years.    
 
1.5.2 Inhibitors of carboxyltransferase 
In contrast to the BC domain, a number of inhibitors that target the carboxyltransferase 
domain have been identified and characterized. Of these, haloxyfop, tepraloxydim, and 
pinoxaden each comprise their own herbicide class. A fourth compound, CP-640186, is a 
synthetic inhibitor developed by Pfizer, and was initially identified by high-throughput screening 
for its activities against mammalian ACCs [14, 75].  
 
 
Figure 13.  Small-molecule inhibitors of the carboxyltransferase domain of ACC. CP-640186 
binds the dimer interface of the CT domain. For the herbicides haloxyfop, tepraloxydim, and 
pinoxaden, the points of CT anchoring are indicated with the red boxes. 
 
Although the herbicides haloxyfop, tepraloxydim, and pinoxaden are widely used in 
commercial agriculture, and are commonly used as herbicides to target the plastid ACCs of 
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invasive weed species, the only available structural data are of each herbicide in complex with 
the CT domain of yeast ACC [75-77]. These herbicides target the CT active site by outcompeting 
acetyl-CoA for the substrate-binding site. Although their overall chemical structures are quite 
diverse, they make two similar points of contact with the CT domain. Figure 13 indicates the 
points of attachment to the enzyme, which is revealed to be an oxyanion hole located adjacent to 
a small methyl group. This conservation in the structures of the herbicides suggests that acetyl-
CoA takes on a similar conformation at some point during catalysis.  
 
1.6 Conclusion 
In humans, the family of biotin-dependent carboxylases consists of five enzymes (ACC1, 
ACC2, PCC, MCC, and PC) with essential roles in energy metabolism and homeostasis. All five 
enzymes assemble as holoenzyme complexes and share a common two-part mechanism: an 
initial ATP-dependent carboxylation of a prosthetic biotin group, followed by the transfer of the 
carboxyl group to an acceptor molecule. The metabolic significance of the carboxylases is 
evident from the severe physiological consequences that result when there is a deficiency in the 
enzymatic activities of ACC1, PCC, MCC, or PC. While many disease-associated mutations 
have been identified for these enzymes, the absence of structural data on their holoenzymes has 
precluded further studies on the molecular consequences of the mutations. Before I began my 
dissertation research, the only holoenzyme structure of a biotin-dependent carboxylase was that 
of pyruvate carboxylase (PC). However, PC recognizes a structurally distinct substrate compared 
to ACC1/ACC2/PCC/MCC, which recognize acyl-CoA esters. Therefore, a primary goal of my 
graduate research was to investigate the holoenzyme assembly of an acyl-CoA carboxylase.  
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In this dissertation, I present the major findings from my research on this family of 
enzymes. Chapter 2 chronicles the elucidation of the PCC crystal structure, which reveals 
several novel findings, including a novel domain that is essential for the holoenzyme 
architecture, the binding mode of BCCP-biotin to the CT active site, and the mapping of disease 
mutations onto the structure to predict their effects on enzymatic stability and activity. To 
investigate the determinants of substrate preference between PCC and MCC, I next focus on the 
structure of MCC, described in Chapter 3. From the MCC structure, I observe a surprising CT 
domain rearrangement compared to PCC, which is an unanticipated finding considering the high 
sequence identity between the two enzymes. I also observe significant differences in the overall 
structure of the MCC holoenzyme. The results of my dissertation work have produced the first 
two holoenzyme structures of CoA-recognizing biotin-dependent carboxylases, and have paved 
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Chapter II  
 
Structural and biochemical studies of propionyl-CoA carboxylase 
 
 
Propionyl-CoA carboxylase (PCC; EC 6.4.1.3) is a member of the biotin-dependent 
carboxylase family and its activities are essential for metabolizing odd-carbon fatty acids, 
cholesterol, and several amino acids. PCC is highly conserved from bacteria to humans, and 
exists as a 750-kDa α6β6 holoenzyme in the mitochondrial matrix of animals. Its importance for 
human health is evident: over a hundred genetic mutations in human PCC have been linked to 
propionic acidemia, which is an inherited disorder characterized by acute metabolic deficits. 
Although an abundance of clinical and functional data exists for PCC, along with a small number 
of structural studies on its constituent domains, there was no published data on the holoenzyme 
of any PCC prior to our investigations. In order to understand how PCC works, and to gain 
insight on the functions of other biotin-dependent carboxylases, we set our sights on obtaining a 
high-resolution structure of the PCC holoenzyme, with additional structural and functional 
characterizations to investigate its mechanistic details. A retrospective survey of highlights in 
PCC research is presented first, followed by the details of our achievements in understanding the 
architecture of this vital macromolecule, as well as a discussion of ongoing questions in the field. 
 
2.1 Introduction to PCC 
 
PCC was first identified in 1957, when the carboxylation of propionyl-CoA to 
methylmalonyl-CoA in porcine heart extracts was found to be an ATP-dependent process [1, 2]. 
In particular, two reactions could be catalyzed with the crude enzyme preparation: 
 
 
ATP + fluoride  ADP + fluorophosphate                                  (1) 




Reaction (2) is the net reaction catalyzed by PCC. However, by recognizing that this 
enzyme could independently coordinate the removal of orthophosphate from ATP even in the 
absence of propionyl-CoA [3], Tietz et al. identified a hallmark of PCC – its dual catalytic 
activities housed within a single enzyme – that continues to be studied to this day.  
 PCC is an essential human enzyme for a number of metabolic transformations. It is 
directly involved in the catabolism of cholesterol, valine, threonine, isoleucine, and methionine, 
as well as certain fatty acids. Of all the nutrient groups that are essential for a balanced diet, 
dietary fats rank the highest in caloric content and contribute significantly to the body’s energy 
reserves. The breakdown of fatty acids involves rounds of β-oxidation for the iterative removal 
of two-carbon acetyl-CoA units; if the fatty acid contains an odd number of carbon atoms, the 
oxidation terminates in a three-carbon compound, propionyl-CoA.  
 
 
Figure 1.  Propionyl-CoA can be fully oxidized to CO2 through the TCA cycle. The reactions 
linking PCC activity to the TCA cycle are shown on the right. Following PCC activity, the 
methylmalonyl-CoA product undergoes racemization and epimerization before transforming into 
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 In healthy individuals, PCC carboxylates the α-carbon of propionyl-CoA to produce D-
methylmalonyl-CoA, which undergoes additional epimerization and rearrangement to yield 
succinyl-CoA for entry into the citric acid cycle (Figure 1). Alternatively, succinyl-CoA can 
combine with glycine to form δ-aminolevulinic acid, which represents the first committed step 
for porphyrin (heme) biosynthesis [4]. In individuals with propionic acidemia, a deficiency in 
PCC activity excludes propionyl-CoA from its usual metabolic fates. Instead, propionyl-CoA is 
converted to propionic acid and methylcitrate, and their buildup in the bloodstream can lead to 
the dangerous lowering of blood pH (acidemia) and inhibition of the citric acid cycle, 
respectively [5, 6]. Additional symptoms may also develop from the accumulation of these toxic 
metabolites throughout the body. A detailed overview of propionic acidemia, along with its 
incidence rates, pathophysiology, and current treatment options, will be discussed later.  
PCC is classified within the family of biotin-dependent carboxylases, and in humans 
there are four additional members: two isoforms of acetyl-CoA carboxylase (ACC1 and ACC2), 
methylcrotonyl-CoA carboxylase (MCC), and pyruvate carboxylase (PC). All five enzymes 
assemble as holoenzymes, are highly conserved among living organisms, and there is significant 
structural homology between their functional domains as well. Figure 1 is a schematic 
representation of the conserved domain structures shared between members of the biotin-
dependent carboxylases.  
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Figure 2.  Conserved domains of biotin-dependent carboxylases from bacteria to humans. 
Colors are assigned based on sequence homology. The CT domain of PC is structurally distinct, 
and is colored accordingly. The same domains are present in each enzyme, although the method of 
assembly presumably varies among different enzymes, forming the basis for structural diversity. 
The scale bar indicates the number of amino acids. Adapted from [7]. 
 
 
There are three conserved domains found in all family members: the biotin carboxylase 
(BC) and carboxyltransferase (CT) domains, which mediate catalysis; and the biotin carboxyl 
carrier protein (BCCP), which employs a prosthetic biotin group to ‘shuttle’ reaction 
intermediates between BC and CT. In humans, the BC and BCCP domains are encoded on the 
PCCA gene, and the CT domain is encoded on the PCCB gene. PCCα and PCCβ are expressed 
as separate polypeptide chains, and are targeted to the mitochondria by means of their amino-
terminal targeting sequences, which are cleavable localization signals that hone in on the 
organelles’ membrane potential differences [8]. Interestingly, studies in rats have suggested that 
biotinylation of the BCCP domain may not take place until after PCCα is imported into the 
mitochondrial matrix [9, 10].  
In addition, there are many similarities between the BC, CT, and BCCP domains of 
different biotin-dependent carboxylases; in spite of this, each enzyme maintains a distinct 
preference for its particular carboxylation target. These properties, along with the direct 
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relevance of biotin-dependent carboxylases for human health, have served as major incentives 
for the structural studies of these enzymes, with PCC as a prime candidate. 
From a structural perspective, PCC is a challenging target, due to its size and complexity. 
A simplified approach is to first obtain high-resolution structures of the individual domains, 
followed by modeling the structures into low-resolution electron density maps of the 
holoenzymes. The domain structures would be important accomplishments in their own right, as 
they are highly conserved between the different carboxylases, contain the catalytic centers, and 
also serve as targets of enzymatic inhibitors and regulators. The crystal structures of BC, BCCP, 
and CT from E. coli are shown in Figure 2. 
 
 
Figure 3.  Crystal structures of biotin carboxylase (BC), biotin carboxyl carrier protein 
(BCCP), and carboxyltransferase (CT) from E. coli ACC. (A) BC is a dimer, with ADP, biotin, 
HCO3-, and Mg2+ bound in the active site of each monomer [11]. (B) BCCP is biotinylated at a 
conserved Lys. The thumb feature is absent in human ACC [12]. (C) CT is a dimer of two stacked 
monomers, and the CT active sites are located at the monomer interface [13]. The sequence 
identities between these structures and their HsPCC homologs are (L-R): 49%, 36%, and 27%. 
 
 The structural details will not be addressed here, but a brief review of the major 
architectural features will facilitate subsequent discussions. E. coli biotin carboxylase is a 98-
kDa dimer, with each monomer’s active site situated 25 Å away from the dimer interface. Upon 
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ATP binding, the distal ends of the BC domain change conformation to form a ‘lid’ over the 
active site [14]. The structure of E. coli BCCP (9 kDa, truncated form) was determined to be a 
‘capped’ beta sandwich, with the biotinylated lysine located at the end of a hairpin loop 
connecting symmetric halves of the molecule [12]. The structure of E. coli CT (72 kDa) contains 
two stacked monomers. Each monomer comprises two subunits (α and β), which are equivalent 
to the N and C sub-domains in eukaryotic CT. The CT active site is located at the stacking 
interface, in a deep groove formed by α subunit from one monomer, and the β subunit from 
another protomer. Therefore, CT must assemble as a α2β2 heterotetramer.  
 The hallmark mechanism of PCC and other biotin-carboxylases involves the BC and CT 
domains, and a mobile entity for shuttling biotin/carboxybiotin between their active sites. The 
original model for communication between the active sites involved a biotin ‘swinging-arm’ 
[15]. However, the crystal structures of pyruvate carboxylase (PC) revealed that the distance 
between BC and CT active sites was beyond the reach of biotin, even in its fully-extended 
conformation [16, 17]. Instead, the entire BCCP-biotin complex was proposed to translocate 
between BC and CT, in what is now termed the ‘swinging-domain’ model (Figure 10, Chapter I).  
In the absence of a PCC holoenzyme structure, it is unclear whether PCC adopts the 
swinging-arm or swinging-domain model. The CT domain of PC is distinct from the other 
carboxylases, in that they primarily target acyl-CoA substrates, while pyruvate is a much smaller 
organic molecule. In addition, the primary sequences of the CT domains of PC and acyl-CoA 
carboxylases are very different. Therefore, efforts toward obtaining a crystal structure of a 
biotin-dependent acyl-CoA carboxylase, such as PCC, were necessary to understand the function 
of this family of enzymes. 
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The stoichiometry of the PCC holoenzyme was predicted to be an α6β6 dodecamer as 
early as 1982 [18], but the exact arrangement of α and β subunits was not known. In 2004, the 
first crystal structure of PCCβ was determined to be a hexameric ring, which bore a surprising 
resemblance to the 12S transcarboxylase structure solved the year earlier. In 2005, the structure 
of Mycobacterium tuberculosis AccD5 was also solved and was found to be highly similar to the 
previous two structures. The crystal structures of all three enzymes are shown in Figure 4. 
 
Figure 4. Crystal structures of the acyl-CoA-recognizing subunits of (a) P. shermanii 
transcarboxylase 12S [19], (b) S. coelicolor PCCβ [20], and (c) M. tuberculosis AccD5 [21]. 
The subunits assemble into a hexamer, and the structures are viewed from the top of each 
hexamer. Each protomer is colored separately.  
 
 
The structures of transcarboxylase 12S, PCCβ, and AccD5 are hexameric rings with 32 
symmetry. Each hexamer is a trimeric assembly of dimers, and the dimer is the basic functional 
unit for catalysis because the active sites are formed at the interface of two protomers. The 
extensive interactions between protomers help to maintain the structural integrity of the hexamer, 
and also lend the possibility of cooperativity during catalysis. Although there has been evidence 
for synergism between the dual active sites of E. coli CT (which assembles as an α2β2 dimer) 
[22], the existence of long-range communication throughout a hexamer has yet to be 
demonstrated. In addition, because the overall structures of the hexamers are very similar, it is 
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likely that discrimination between specific acyl-CoA carboxylases is limited to a small region 
within each hexamer. Therefore, it is possible to observe the binding modes of the various CT 
substrates and establish a model for substrate selectivity in PCC as well as for the other biotin-
dependent carboxylases.  
The existence of multifunctional ACC/PCCs with specificity for both acetyl- and 
propionyl-CoA has been observed for a number of archaeal species, including Metallosphaera 
sedula and Acidianus brierleyi [23, 24]. However, the majority of ACCs and PCCs exhibit a 
clear preference for one substrate. The structure of S. coelicolor PCCβ (Figure 4B) was 
elucidated as a 400-kDa protein complex with bound biotin and propionyl-CoA. By investigating 
the protein-ligand contacts in the active site binding pocket, Diacovich et al. identified a residue 
(Asp422) whose mutation to Ile converted the specificity of the holoenzyme from propionyl-
CoA to acetyl-CoA [20]. This Asp residue appears to be conserved in a number of other PCCs, 
and its proposed identity as a ‘molecular switch’ holds the potential for understanding PCC 
substrate recognition, and possibly for modifying PCC function as well. An obvious implication 
of the latter is the prospect of restoring PCC function in individuals with deficient PCC activity 
(propionic acidemia). 
PCC is a robust enzyme, and its activity is augmented in the presence of certain 
activators, including several monovalent cations (NH4+, K+, Cs+) [25]. While none of these 
cations are absolutely required for enzyme function, the addition of 8 mM K+ to porcine heart 
PCC resulted a 25-fold stimulation in its activity [26]. NH4+ and Cs+ were also found to activate 
PCC, although to a lesser extent than K+. The PCC from bovine liver is also activated by K+, and 
K+ may increase the affinity of the enzyme for its substrates. To this end, Georgio et al. obtained 
fluorescence data suggesting that K+ triggers the closed conformation of biotin carboxylase in 
 45 
order to bind ADP and initiate catalysis [25]. Potassium may also function as a regulator of PCC 
activity within cells, due to the correlation between increasing potassium concentration and 
increased catalytic activity. In the absence of a PCC holoenzyme structure, however, it is 
difficult to ascertain how potassium interacts with PCC and stimulates its function.  
PCC is a crucial enzyme, and PCCα-/- mice die within 36 hours of birth [27]. In humans, 
propionic acidemia (PA) is an autosomal recessive disorder characterized by the buildup of 
unprocessed PCC substrates and byproducts, including ketone bodies, ammonia, and propionic 
acid. If unchecked, the accumulation of toxic metabolites eventually leads to developmental 
delays, acute and/or chronic neurological deficits, and severe immune deficiencies [28, 29]. 
There is currently no cure for PA, but symptoms and relapses may be controlled by a strict 
adherence to a low-protein diet, carnitine supplementation, and metronidazole administration to 
control the amount of propionic acid produced by intestinal flora [30]. Although there are over a 
hundred documented mutations within PCC that have been linked to cases of PA, the 
consequences of these mutations on the structure and function of the enzyme are not clearly 
defined. In addition, PA spans a wide range of phenotypes, from acute symptoms at birth to late-
onset presentations in adults. In the United States, the incidence rate of propionic acidemia is 1 
per 35,000 live births, and the disease typically exhibits a progressive pathology. The long-term 
survival rate for patients exhibiting early-onset PA is 67% [31], which testifies to the importance 
of PCC research for understanding this disease. 
Propionyl-CoA carboxylase is an essential metabolic enzyme with obvious implications 
for human health, but studies regarding its structure and biochemistry have been limited. A 
comprehensive knowledge of its activities would also have immense relevance for other 
members of the biotin-dependent carboxylase family. The absence of a PCC holoenzyme 
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structure has precluded further studies of the interactions between BC and CT, particularly those 
governing their association, the basis for biotin (or BCCP-biotin) translocation, the overall 
catalytic mechanism, and the consequences of gene mutations associated with propionic 
acidemia. These questions represent the bridging features in our understanding of PCC activity 
and set the stage for our investigations of the PCC holoenzyme, in hopes of understanding its 
structure, function, and role in maintaining metabolic vitality.  
 
2.2 Experimental Procedures 
 
Protein purification and mutagenesis 
 
Genomic DNA for Ruegeria pomeroyi and Roseobacter denitrificans was obtained from 
ATCC and the full-length PCCs were cloned as bicistronic expression constructs featuring N-
terminal hexa-histidine tags in pET-28a (Novagen). To generate the R. pomeroyi + R. 
denitrificans chimera (RpαRdβ), the α subunit from R. pomeroyi PCC (RpPCCα) was subcloned 
in place of the α subunit within the R. denitrificans PCC (RdPCC) construct, yielding a final 
sequence of RBS-(His)6-[RdPCCβ]-RBS-[RpPCCα]. Human PCC was similarly prepared, using 
a cDNA source. “RBS” indicates a ribosomal binding site. The PCCs were over-expressed in E. 
coli BL21 Star (DE3) cells (Invitrogen) in LB media + 1 mM IPTG, supplemented with 20 mg/L 
biotin, and expressed at 20°C overnight. The resulting cell paste was resuspended in Lysis Buffer 
(20 mM Tris-HCl (pH 7.5), 250 mM NaCl, 5% (v/v) glycerol, 0.1% (v/v) Triton X-100, and 5 
mM dithiothreitol (DTT)) and lysed by sonication. The clarified lysate was incubated with Ni-
NTA agarose beads (Qiagen) at 4°C, and the beads were washed with Wash Buffer (20 mM Tris-
HCl (pH 7.5), 250 mM NaCl, 10 mM imidazole, and 10 mM β-mercaptoethanol). The eluent was 
collected in Elution Buffer (Wash Buffer + 250 mM imidazole) and injected onto a Sephacryl S-
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300 size-exclusion column (GE Healthcare). The purified protein was concentrated to 15 mg/mL 
and flash-frozen with liquid nitrogen in Storage Buffer (20 mM Tris-HCl (pH 7.5), 250 mM 
NaCl, 5 mM DTT, and 5% (v/v) glycerol). Protein samples were stored at -80°C and thawed on 
ice for subsequent experiments. Biotinylation of the α subunit was confirmed using an avidin 
gel-shift assay. The N-terminal hexahistidine tags were not removed for crystallization.  
All mutants were generated with the QuikChange kit (Agilent) and were sequenced to 
confirm the presence of mutations. The expression and purification schemes for the mutants were 
the same as those described for the wild-type enzymes. 
 
Kinetic studies of PCC 
 
The catalytic activity of PCC was measured using a coupled enzyme assay, which links 
the consumption of ATP by the BC domain to the disappearance of NADH [32]. The reaction 
buffer contained 100 mM HEPES-KOH (pH 8.0), 0.5 mM ATP, 8 mM MgCl2, 40 mM KHCO3, 
0.5 mM propionyl-CoA or acetyl-CoA, 0.2 mM NADH, 0.5 mM phosphoenolpyruvate, 7 U 
lactate dehydrogenase, 4.2 U pyruvate kinase, and 200 mM KCl. All reagents were obtained 
from Sigma. The reaction was initiated by adding 2 µg of protein (at 15 mg/mL) to 100 µL of 
reaction buffer, and the progress was monitored by tracking the absorbance at 340 nm for 5 min. 
 
Crystallization of the PCC holoenzymes 
 
Initial crystallization conditions were identified using commercial sparse-matrix and grid 
screens (Emerald BioSystems, Hampton Research, Qiagen). Crystals were produced using the 
microbatch method under paraffin oil (Hampton Research), in a 1:1 drop ratio of protein to 
precipitant solution. Crystals were cryoprotected via immersion in the precipitant solution 
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supplemented with glycerol, for a final PEG + glycerol concentration of 35%, and were flash-
frozen in liquid nitrogen prior to data collection. 
Crystals of the RpαRdβ chimera: the protein samples were at 15 mg/mL and the 
precipitant solution contained 0.1 M HEPES-KOH (pH 8.0), 0.2 M NaCl, 21% (w/v) PEG-3350, 
and 16% (v/v) glycerol. After 2 weeks at 4°C, box-shaped crystals of 0.6 mm in length were 
observed, but most exhibited weak X-ray diffraction. 
Crystals of RpPCC: the protein samples were concentrated to 15 mg/mL and the 
precipitant solution contained 0.2 M succinic acid (pH 6.5), 22% (w/v) PEG-3000, and 2.2% 
(w/v) benzamidine-HCl. After 5 days at 20°C, small prismatic crystals of 0.25 mm in length 
appeared. The majority of these crystals also exhibited weak X-ray diffraction, and extensive 
screening was required to identify crystals suitable for data collection. 
 
Data collection and structure determination 
 
X-ray diffraction data for the chimeric RpαRdβ and RpPCC were collected at 100 K, at 
the X29A beamline of the National Synchrotron Light Source (NSLS) at Brookhaven National 
Laboratory. All diffraction images were processed and scaled with HKL-2000 [33].  
For the RpαRdβ chimera, an X-ray diffraction data set was collected at 3.2-Å resolution, 
and the crystal belonged to space group P1, with cell parameters of a = 133.9 Å, b = 159.2 Å, c = 
153.7 Å, α = 113.9°, β = 101.0°, and γ = 109.0°. The asymmetric unit (and the unit cell) 
contained a single α6β6 dodecamer. The structure was solved with the molecular replacement 
program Phaser, using the following as search models: the BC subunit of E. coli ACC [11], the 
CT subunit of S. coelicolor ACC [20], and the BCCP domain of S. aureus PC [17]. The atomic 
model was built into the electron density map using O [34], and the structure was refined using 
CNS [35, 36] and deposited into the Protein Data Bank (accession code: 3N6R). 
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For RpPCC, an X-ray diffraction data set was collected at 3.2-Å resolution, and the 
crystal belonged to space group P3, with cell parameters of a = b = 246.3 Å and c = 133.5 Å. 
Each asymmetric unit contained one α2β2 unit, positioned alongside the crystallographic 
threefold axis. The crystal exhibited merohedral twinning (twinning fraction of 0.49). The 
structure was solved with the molecular replacement program COMO [37], using the BC subunit 
of E. coli ACC [11] and the CT subunit of S. coelicolor ACC [20] as search models. Twin 
refinement was executed using CNS. The crystallographic information is summarized in Table 1. 
 
Table 1. Crystallographic data and refinement statistics 
 RpαRdβ chimera RpPCC 
Crystal data   
     Space group P1 P3 
     Unit cell dimensions a=133.9Å, b=159.2Å, 
c=153.7 Å, α=113.9°, 
β=101.0°, γ=109.0°  
a=b=246.3 Å, 
c=133.5 Å,  
α=β=90°, γ=120° 
Diffraction dataa   
     Wavelength (Å)  1.075 Å   1.075 Å  
     Resolution range (Å) 30–3.2 30–3.3 
     Redundancy  1.9 (1.7) 2.8 (2.0) 
     Completeness (%) 92 (80) 95 (87) 
     <I/σI> 8.7 (2.0) 7.7 (1.7) 
     Rmerge (%) 8.4 (34.2) 10.6 (39.6) 
Structure refinement   
     No. of reflections used 155,003 125,474 
     Rwork / Rfreeb (%) 21.2/24.5 (31.9/34.0) 17.0/24.4 (24.9/33.5) 
     RMSD bond lengths (Å) 0.012 0.010 
     RMSD bond angles (°) 1.6 1.4 
aValues in parentheses refer to the highest-resolution shell. 
bRfree = free R factor, based on a random sample of 5% of reflections.  
 
 
Electron microscopy (EM) studies 
 
All EM studies were performed by our collaborators in the laboratory of Dr. Z. Hong 
Zhou at the University of California, Los Angeles. Samples of purified H. sapiens PCC were 
diluted to 70 µg/mL in PBS prior to use. For negative stain experiments, 3 µL of diluted sample 
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was spotted onto a carbon-film-coated, glow-discharged, 300-mesh copper grid, and excess 
sample was blotted away after 1 min. The sample was twice stained using 2.5% uranyl acetate 
and air-dried. For cryo-EM experiments, frozen hydrated particles of HsPCC were suspended 
across Quantifoil carbon grids by plunge-freezing after dilution. Cryo-EM experiments were 
performed using a JEOL 1200EX electron microscope, and images were recorded on Kodak 
SO163 films at 50,000X magnification and digitized using a step size of 14 µm/pixel, 
corresponding to 2.8 Å/pixel on the sample. All EM images were produced with Chimera [38].  
 
 
2.3 Preliminary studies on PCC  
 
 PCC has been a long-sought target in our laboratory. In 2003, the first studies of the α 
and β subunits from human PCC (HsPCC) were conducted by Yang Shen, a graduate student and 
subsequent postdoctoral fellow in the lab. Although the α subunit formed an aggregate upon 
large-scale purification, the β subunit was purified and yielded good-quality crystals that 
diffracted to 2.4-Å resolution. The structure of HsPCCβ was determined to be a hexamer (not 
shown), and is very similar to the hexamers shown in Figure 4. In order to investigate the 
workings of a full-length PCC, structural studies of the human holoenzyme were also pursued. 
HsPCC was purified to homogeneity and produced crystals that diffracted to 5.5-Å resolution 
(space group R3), but the crystals exhibited near-perfect twinning and could not be improved. 
Additional efforts to produce a high-resolution holoenzyme structure through truncation mutants 
and two-species hybrids were not successful.  
 I assumed responsibility for the PCC project in Spring 2008, and began my 
investigations by screening through a collection of bacterial PCCs with high sequence identity to 
the human enzyme. This approach was taken with the assumption that proteins possessing 
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similar primary sequences are also likely to exhibit similar three-dimensional structures. Each 
holoenzyme was generated as a bicistronic expression construct, which places tandem coding 
sequences under the control of a single promoter (Figure 5). Although the choice of an N- or C-
terminal histidine tag was arbitrary, it was essential that only one subunit (either PCCα or PCCβ) 
carried the tag in the final construct. This modified pull-down approach ensured that the 750-kDa 




Figure 5. Synthesis of the bicistronic expression construct used to express PCC holoenzymes. 
(A, B) PCC subunits were individually screened for protein overexpression and solubility. (C) 
PCC holoenzymes were produced by subcloning the PCCα gene and its upstream ribosomal 
binding site into the PCCβ expression plasmid. Although PCCα is not tagged in the final 
construct, the formation of the holoenzyme allows the entire complex to be purified using the 
PCCβ tag, then separated from the PCCβ hexamer based on size. 
 
 
The best candidate from this screen of bacterial PCCs was isolated from Ruegeria 
pomeroyi, a Gram-negative soil bacterium whose PCC shares 60% sequence identity with its 
human homolog. RpPCC was purified and produced small prismatic crystals (Figure 6B) that 
diffracted to 3.3-Å resolution after extensive screening, which was a significant improvement 
over the HsPCC crystals. Although the RpPCC crystals also exhibited perfect twinning (space 
group P3), the diffraction data were of significantly high resolution to determine the locations of 
the BC and CT domains by molecular replacement and produce a model of the PCC holoenzyme.  
The structure of RpPCC features the same hexameric arrangement of PCCβ subunits that 
was observed in S. coelicolor (Figure 4B). Unexpectedly, the BC subunits are situated on the 
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periphery of the hexamer, with three subunits above the hexameric ring and another three 
subunits below, thereby forming an α3β3β3α3 dodecamer complex. As a result, the α subunits are 
responsible for mediating the packing of RpPCC molecules within the crystal, and presumably, 
are the cause of the twinning problem. 
With the intent of altering the crystal packing, several PCC chimeras were generated by 
combining α and β subunits from different bacterial species. One particular construct paired the α 
subunit from R. pomeroyi with the β subunit from Roseobacter denitrificans, a marine bacterium 
whose PCCβ subunit shares 88% sequence identity with RpPCCβ. This chimeric PCC was 
purified and produced block-shaped crystals (Figure 6C).  
 
 
Figure 6.  Crystals of PCC holoenzymes from H. sapiens, R. pomeroyi, and a R. pomeroyi/R. 
denitrificans chimera. Crystallization conditions are detailed in the Experimental Procedures. 
HsPCC crystals were obtained from a modified coexpression construct that omitted 15 residues 
from the N-terminus of HsPCCβ, while the bacterial crystals contain their respective full-length 
PCCs. The crystals of HsPCC were obtained by Yang Shen. 
 
 
After screening through several hundred candidates, a single crystal produced an X-ray 
diffraction data set that extended to 3.2-Å resolution. Most importantly, the crystal was not 
twinned (space group P1), and the structure was solved by molecular replacement. The search 
models consisted of the BC subunit from E. coli ACC, the BCCP domain of S. aureus pyruvate 
carboxylase, and the CT subunit from S. coelicolor ACC. 
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2.4 Structure of the 750-kDa holoenzyme of propionyl-CoA carboxylase 
 
 The structure of the RpαRdβ PCC holoenzyme is roughly cylindrical (Figure 7). The β6 
hexamer forms the central core and is composed of two layers, each with three β protomers. This 
hexamer is very similar to the hexamer structure observed for ScPCCβ (Figure 4B). The six α 
subunits are monomeric, and are spaced 120° apart on the top and bottom faces of the β6 
hexamer, for a total of three α subunits per face, and the overall structure possesses 32 symmetry. 
 Although the chimera’s bacterial subunits were selected for their similarity to the human 
PCC enzyme, the extent of their structural similarity was not known based on the sequence 
comparison alone. In order to address this potential disparity, the laboratory of Z. Hong Zhou 
(UCLA) succeeded in producing a cryo-electron microscopy (cryo-EM) reconstruction of human 
PCC at 15-Å resolution, and the resulting model is in excellent agreement with the crystal 
structure of the chimeric PCC (Figures 7C, 7D). The most significant difference between the two 
structures is a minor shift in the position of the BCCP domain (Figure 7D). In addition to 
demonstrating that the structure of HsPCC is highly similar to that of RpαRdβ, the cryo-EM 
reconstruction also indicates that the PCC holoenzyme maintains the same overall conformation 




Figure 7.  Structure of the PCC holoenzyme [39]. (A) Looking down the threefold symmetry 
axis of the RpαRdβ chimera of propionyl-CoA carboxylase (PDB code 3N6R). (B) Looking down 
the twofold symmetry axis. The gray envelopes in (C) and (D) are cryo-EM reconstructions of 
human PCC at 15-Å resolution with the crystal structure of the RpαRdβ chimera docked into the 
envelopes, and are viewed in the same orientations as (A) and (B). The crystal structure figures 





A primary incentive for obtaining the PCC holoenzyme structure was the possibility of 
elucidating a decades-old mystery: the connectivity between the BC and CT catalytic domains, 
and how BCCP mediates catalysis in this 750-kDa holoenzyme. The issue of connectivity is 
addressed first. 
 When contemplating the potential domain connections within the PCC holoenzyme, it is 
plausible to assume that the interaction between the α and β subunits is mediated by the BC and 
CT domains. Both domains are large and well conserved, and possess ample surface area on 
which to form inter-domain contacts. However, a close inspection of the RpαRdβ holoenzyme 
structure reveals that the BC domain actually hovers over the edge of the β6 hexamer (Figure 
7A), and there is very little interaction with the CT domains. Instead, the majority of the α-β 
subunit interactions are mediated by a new domain, which is colored in orange. As a result of its 
coordinating the interactions between the BC and CT domains, this novel domain has been 
designated the ‘BT’ domain. 
 
2.4.1 Identification of a novel domain: the BT domain 
 
Prior to the discovery of the BT domain within the PCC holoenzyme structure, its 
position within the primary sequence of PCCα was considered to be little more than a 
placeholder between two conserved domains. This ‘placeholder’ was assumed to be a somewhat 
flexible linker joining BC and BCCP, and not much attention was paid to it. After all, the BC and 
CT domains contained the catalytic centers, the BCCP domain mediated the shuttling of reaction 
intermediates, and each domain that was necessary for PCC catalysis had been accounted for in 
the preliminary structure of the holoenzyme. 
However, after determining the positions of the BC, BCCP, and CT domains within the 
holoenzyme, there remained a significant portion of unassigned electron density between the 
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BC/BCCP and CT domains. After building in the missing residues, the structure of the BT 
domain was revealed, and more importantly, its function as the bridging feature between the α 
and β subunits was established. The structure of BT is shown in Figure 8, along with the PC 
tetramerization (PT) domain from S. aureus pyruvate carboxylase, with which BT shares weak 
structural similarity. 
 
Figure 8. Structures of the (a) BT domain from PCC and (b) the PT domain from S. aureus 
pyruvate carboxylase (SaPC). While BT is encoded as a single domain within the primary 
sequence of PCCα, the PT sequence is interrupted by the CT domain of SaPC (see Figure 1) at the 
joint between Helix α1 and the start of the β sheet. 
 
 
 The BT domain is located between the BC and BCCP domains within the primary 
sequence of PCCα, and its structure consists of an eight-stranded anti-parallel β-barrel with a 
long helix situated in the center of the barrel. The importance of BT in maintaining the overall 
architecture of PCC is evidenced by its extensive interactions with the β6 hexamer (CT subunits): 
of the 1,950 Å2 of buried surface area between the α and β subunits, BT accounts for over 70% 
of the interactions, whereas BC and BCCP account for 10% and 15%, respectively. In particular, 
the distal loop in the BT domain mediates a majority of the inter-subunit contacts; this makeshift 
‘hook’ (viewed as the bottom-most loop in Figure 8A) forms a number of salt bridges as well as 
hydrogen bonds with the β subunits. At the C-terminus of BT, helix αW (Figure 8A) also helps 
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to stabilize the interactions of the α and β subunits, although to a lesser extent than the hook, and 
the stabilizing forces are largely through hydrophobic contacts.   
A retrospective analysis of the PCCα primary sequence using secondary structure 
prediction did indeed indicate the presence of a long helix with eight accompanying beta strands. 
However, because the fold of the BT domain was entirely unprecedented, it would have been 
unlikely that the tertiary structure of BT was correctly predicted by sequence analysis alone. A 
search for structural homologs of BT in the Protein Data Bank did not return any results. There 
is, however, a small degree of structural similarity between BT and PT, which is the PC 
tetramerization domain that mediates tetramer formation in pyruvate carboxylase. PT, however, 
consists only of a four-stranded anti-parallel β-sheet wrapped around a considerably shorter helix 
(Figure 8B).  
 
2.4.2 PCC employs a swinging domain for BCCP-biotin translocation  
 
Although the exact role of BCCP in catalysis is not completely answered by the current 
holoenzyme structure, one conclusion is apparent: the BC and CT active sites of PCC are 
separated by 55 Å, thus supporting the ‘swinging-domain’ model for biotin translocation 
(Figures 4, 9A). The case for BCCP acting as the mobile unit is also assisted by the small change 
in its position between the cryo-EM structure of HsPCC and the crystal structure of the RpαRdβ 
PCC chimera. In the crystal structure, BCCP-biotin is observed binding in the CT active site 
(which also accommodates propionyl-CoA), while the cryo-EM reconstruction places the BCCP 
domain closer to the BC domain. One possible explanation for the discrepancy is that BCCP-
biotin is stabilized with the CT active site in the protein crystal (which contains approximately 
50% solvent content), but an aqueous environment may provide alternative stabilizing 
contributions to lodge the flexible domain in a different conformation.  
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Figure 9. Locations of the active sites and disease-associated gene mutations in the PCC 
holoenzyme. (A) Molecular surface representation of one α subunit and a β2 dimer. The bound 
positions of ADP and bicarbonate in complex with E. coli BC [11] and CoA in complex with 
transcarboxylase 12S [19] are shown. The BC and CT active sites are separated by 55 Å. Domains 
are colored in the same manner as in Figure 7. (B) Cartoon representation of (A), with the 
locations of propionic acidemia-associated mutations indicated by spheres. The position of CoA 
binding is indicated with the pink molecule. 
 
 
2.4.3 Disease mutations can impair PCC catalysis and/or holoenzyme stability 
  
 Propionic acidemia (PA) has been a well known genetic disorder for many decades, due 
to its acute clinical phenotype and its relatively high incidence rate. Our structural studies of the 
PCC holoenzyme have provided a valuable tool for understanding the consequences of many 
PA-associated gene mutations, and may help in the development of disease therapies as well.  
 Figure 9B indicates the sites of amino acids that are substituted as a result of PA-related 
mutations. The Cα atoms are indicated as spheres on a foundation of an α subunit and a β2 dimer, 
with the latter also indicating the site of propionyl-CoA binding. Several of the mutations are 
found in the vicinity of the BC and CT active sites, and may impede catalysis. The G631R 
mutation within the BT domain is located at its interface with the BC domain, and the 
 59 
substitution of a considerably larger arginine residue is proposed to disrupt the structure. 
Through thermal shift experiments, it was shown that the G631R mutant is much more 
susceptible to denaturation than the wild-type enzyme. 
 To investigate the forces that maintain α-β interactions within the holoenzyme (and 
therefore contribute to PCC’s functionality), we introduced a series of combined mutants at the 
subunit interface. These experiments took advantage of the fact that within the holoenzyme, only 
the β subunit of each holoenzyme is His-tagged, allowing for the concurrent pulldown of the 
untagged α subunit only upon holoenzyme formation. If the α-β interactions are destabilized, α 
will not be present in the eluent fraction (Figure 10). 
 
Figure 10. Effects of propionic acidemia (PA) gene mutations on PCC holoenzyme stability. 
The E. coli cell pellet fraction is indicated with ‘P’ and the soluble supernatant fraction is 
indicated with ‘S’. Three combinations of PA mutations were assessed, and the abbreviations are, 
from left to right: LA+MA (L649A/M640A), LA+LA+MA (L646A/L649A/M650A), and 
RA+RA+LA+MA (R539A/R540A/L649A/M650A). Control lanes of wild-type RpPCC are in the 
lanes labeled ‘PCC’.  
 
  
We determined that PCC is an inherently stable enzyme, and only upon the introduction 
of three simultaneous mutations were we able to induce dissociation of the α and β subunits. The 
subunit interface of PCC is therefore proposed to contain an expansive network of interactions 
that maintain the integrity of the holoenzyme. As such, a single or double PA-associated 
mutation is unlikely to exert much of an effect on the activity of the holoenzyme. 
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Figure 11. The CT active site. (left) Molecular surface representation of the CT binding pocket. 
The modeled binding mode of CoA with the 12S subunit of transcarboxylase is shown. (right) 
Detailed view of the CT active site. Biotinylation occurs on Lys694, which is found within a 
conserved sequence motif (MKM) of BCCP. 
 
  
 The CT active site is located in a deep groove, formed at the interface of an N domain 
from one β protomer and a C domain from another β protomer (Figure 11). BCCP-biotin is also 
observed binding the CT domain. In order to study the potential interactions between propionyl-
CoA and the CT active site, the binding mode of CoA in complex with the 12S subunit of 
transcarboxylase was modeled into the structure. This model reveals that biotin and the CoA 
ligand occupy different ends of the groove, but the acyl group is expected to come within reach 
of carboxybiotin to permit catalysis. In our structure of PCC, biotin is held in a catalytically 
unproductive conformation, but the presence of an actual substrate is likely to extend biotin out 




2.5 Exploring the possibility of a molecular switch for substrate specificity 
 
 Several dual-specificity ACC/PCCs have been identified and were found to carboxylate 
both acetyl-CoA and propionyl-CoA with similar efficiency; however, the majority of ACCs and 
PCCs are selective for their namesake substrate. The recognition of an acyl-CoA occurs in the 
CT active site, which is formed only upon the dimerization of two CT protomers. Although the 
CT domains of acyl-CoA carboxylases are highly conserved across species, and it is unclear how 
each carboxylase can distinguish its preferred substrate from structurally similar analogs. A 
possible explanation is that the CT active site fashions a very specific environment for its 
preferred ligand, and accommodates the molecule’s size, shape, and electrostatics with extreme 
accuracy. As such, it it possible to alter the substrate preferences of an enzyme simply by making 
adjustments to its binding environment. 
 In 2004, Diacovich et al. identified Asp440 of S. coelicolor PCCβ as a ‘molecular 
switch.’ A D440I mutation was observed to dramatically interconvert the enzyme’s substrate 
preferences from propionyl-CoA to acetyl-CoA [20]. In the structure of RpαRdβ PCC, the 
position of Asp440 is occupied by a valine (Figure 11). V440 is in the proximity of the CoA 
substrate’s acyl group, and may hold a similar role in determining substrate preference. In order 
to assess whether this residue truly functions as a ‘switch’, the Ile mutation was introduced into 
both RpPCC (which possesses an Asp at residue 440) and the RpαRdβ chimera. The effects on 
substrate preference and catalysis were monitored using an ATP hydrolysis assay (Figure 12), 





Figure 12. Schematic illustration of the ATP hydrolysis assay. Because none of the reactants or 
products in the PCC-catalyzed reaction (shown in the purple box) can be tracked 
spetrophotometrically, a coupled-enzyme system featuring pyruvate kinase (PK) and lactate 
dehydrogenase (LDH) links the production of ADP to the disappearance of NADH. The reaction 




Table 2. Kinetic data for the substrate preferences of wild-type PCC and its mutants 
 Relative Activity 
 Propionyl-CoA Acetyl-CoA 
RpPCC 1.0 ± 0.1a 0.27 ± 0.04 
RpαRdβ chimera 1.7 ± 0.3 0.15 ± 0.04 
RpPCC (D440I) 2.1 ± 0.2   0.24 ± 0.02 
RpαRdβ chimera (V440I) 1.6 ± 0.2 0.28 ± 0.05 
a The activity of wild-type RpPCC against propionyl-CoA was set to 1.0. 
 
 
In contrast to the results reported by Diacovich et al, the D440I and V440I mutations 
failed to convert the substrate preferences of RpPCC and RpαRdβ to favor acetyl-CoA. It is 
possible that the chemical environment of RpαRdβ is not similar to that of ScPCCβ, and thus 
V440 is not an appropriate candidate for controlling substrate discrimination. In order to 
investigate whether D440 of RpPCC could play a role in determining the fit of substrates within 
the CT binding pocket, various mutations were introduced to alter the shape, size, and 





Table 3. Kinetic data for the substrate preferences of various RpPCC D440 mutants 
 Relative Activity 
 Propionyl-CoA Acetyl-CoA 
RpPCC 1.0 ± 0.1a 0.22 ± 0.02 
D440L 0.12 ± 0.01 0.25 ± 0.05 
D440C 1.0 ± 0.1 0.23 ± 0.06 
D440A 1.1 ± 0.1 0.43 ± 0.05 
D440N 0.29 ± 0.08 0.13 ± 0.06 
D440E 0.10 ± 0.08 0.14 ± 0.03 
a The activity of wild-type RpPCC against propionyl-CoA was set to 1.0. 
 
 
 The kinetic data indicate that the majority of nonconservative mutations failed to alter the 
substrate preference of RpPCC. Although the D440L and D440E mutants exhibited respective 2- 
and 1.4-fold higher activities toward acetyl-CoA, the overall activities are dramatically lower 
than those of wild-type RpPCC. As a result, substrate selectivity may not be determined by a 
single residue; the maintenance of binding site architecture and/or charge may also be involved 
in determining substrate preference.  
 
 
2.6 Preliminary investigations of PCC activation by potassium 
  
Literature reports have demonstrated that the activities of both eukaryotic and prokaryotic 
PCC can be enhanced with K+ and other monovalent ions, with K+ being the most effective 
species. Due to the lack of structural data, the molecular basis of this phenomenon was not clear. 
Our structure of the PCC holoenzyme provides a valuable foundation on which to study the 
mechanism of K+ activation, and determine how the ion specifically activates PCC while 
possessing few to no effects on other biotin-dependent carboxylases.   
 As the effects of potassium on R. pomeroyi PCC had not been previously reported, we 
first sought to characterize its response to K+. In addition, the RpαRpβ PCC chimera was also 
assayed. This chimera is not a naturally existing species, so while its structural data had indicated 
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that it was highly similar to the PCCs of other organisms, it remained of interest to determine 
what kind of catalytic potential a hybrid enzyme could possess. Finally, 3-methylcrotonyl-CoA 
carboxylase was used as a negative control. This enzyme is another biotin-carboxylase and 
shares many characteristics with PCC; however, there are no known reports of enhanced MCC 
activity in response to potassium [41]. 
 These three enzymes were used for an ATP hydrolysis assay (Figure 11) in which the 
standard reaction components were modified ensure that no exogenous potassium was present in 
the reaction buffer. To this end, the HEPES buffer was prepared with sodium hydroxide instead 
of potassium hydroxide, KCl was replaced by NaCl, and KHCO3 was replaced by NaHCO3. In 
order to titrate increasing amounts of potassium into the reaction, the NaCl was progressively 
substituted with KCl to maintain a constant ionic strength within the buffer while increasing the 
concentration of K+. The results of the titrations are shown in Table 4. Each value represents the 
average and standard deviation from three separate trials. 
 
Table 4. Kinetic data demonstrating K+ activation of PCC 
 Relative Activity 




0 1.0 ± 0.08a 1.0 ± 0.3 1.0 ± 0.07 
3 1.0 ± 0.01 1.7 ± 0.08 1.1 ± 0.01 
10 1.1 ± 0.2 1.3 ± 0.1 1.1 ± 0.03 
30 1.7 ± 0.1 1.7 ± 0.1 1.0 ± 0.0 
100 2.9 ± 0.1 3.3 ± 0.1 0.9 ± 0.1 
200 3.9 ± 0.1 3.9 ± 0.04 0.8 ± 0.03 
a The activity of wild-type RpPCC against propionyl-CoA was set to 1.0. 
b The MCC reaction substituted 3-methylcrotonyl-CoA in place of propionyl-CoA 
 
 
 The results of the assay demonstrate a clear activation of both PCC species in response to 
increasing potassium concentration. MCC, as predicted, does not exhibit much variation in 
response to changing potassium levels. Neither RpPCC nor the chimera appeared to reach its 
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maximum catalytic efficiency; therefore, it may be worthwhile to increase the upper 
concentration limit of potassium in order to better understand the extent of its effects. Human 
PCC, in particular, has been reported to demonstrate a 7-fold increase in activity, in response to 
K+ [42].  
 In order to investigate the structural basis of K+ activation in PCC, we prepared crystals 
of the RpαRpβ PCC chimera and soaked them overnight in the presence of the original mother 
liquor, supplemented with 10-200 mM RbCl and CsCl. Although neither of the cations activate 
PCC to the extent of potassium, they are significantly larger in size and their electron density 
within the PCC structure will be more apparent. A preliminary data set was obtained at 4-Å 
resolution for a crystal soaked with Cs+, and a fragment of electron density corresponding to the 
Cs+ ion was observed near the junction of the BT ‘hook’ and the adjacent β subunit. As the 
‘hook’ feature of BT has been demonstrated to mediate a substantial portion of α-β interactions 
within the PCC holoenzyme, it appears possible that the presence of a cation activator at this site 
may help stabilize the holoenzyme for catalysis. Additional studies are necessary to obtain a 
higher-resolution model of Cs+ binding, and the resulting observations can be supplemented with 
mutation studies to identify the structural components of PCC that are involved in recognizing 
and responding to the cation activator.  
 
 
2.7 Structural implications for other acyl-CoA carboxylases 
 
 The elucidation of the PCC holoenzyme structure represented a great leap forward in our 
understanding of biotin-dependent carboxylases. In particular, the structure of a biotin-dependent 
acyl-CoA carboxylase has particular relevance for human health and disease, as four of the 
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enzymes (including PCC) act upon acyl-CoA esters, which are common intermediary 
metabolites in the body. 
3-methylcrotonyl-CoA carboxylase (MCC) is another biotin-dependent carboxylase that 
targets an acyl-CoA ester, and is responsible for carboxylating the γ-carbon of 3-methylcrotonyl-
CoA to product 3-methylglutaconyl-CoA (Figure 13). MCC is essential for leucine metabolism 
in humans, and is also involved in terpene metabolism in some bacteria [43]. Like PCC, MCC is 
also a mitochondrial enzyme in humans, requires ATP and biotin for its function, features the 
same domain architecture and subunit organization, and its deficiency in humans is also 
associated with a genetic disease that shares many symptoms with propionic acidemia. PCC and 
MCC also share significant sequence homology (Figure 13); therefore, it is possible to build a 
homology model for MCC based on the structure of PCC. 
 
Figure 13. Illustration of shared sequence identities between the α and β subunits of PCC 
and MCC from humans and Pseudomonas aeruginosa. The sites of carboxylation on propionyl-
CoA and methylcrotonyl-CoA are indicated with red asterisks. 
 
 
However, there is one key difference between the two enzymes – their respective choice 
of substrate. While PCC carboxylates the α-carbon of propionyl-CoA, MCC accommodates a 
larger substrate and targets its γ-carbon instead (Figure 13). The underlying basis for substrate 
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selectivity between PCC and MCC is expected to lie in their respective acyl-CoA-recognizing 
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Chapter III  
 
Structural and biochemical studies of 3-methylcrotonyl-CoA carboxylase 
 
3.1 Introduction to MCC 
  
3-methylcrotonyl-CoA carboxylase (MCC; EC 6.4.1.4) is another member of the biotin-
dependent carboxylases, and catalyzes the ATP-dependent carboxylation of 3-methylcrotonyl-
CoA to generate 3-methyl-glutaconyl-CoA (Figure 1). MCC is a highly conserved enzyme and is 
found in all walks of life, from bacteria to man. In humans, MCC is a mitochondrial enzyme and 
was predicted to be a 500-800-kDa complex, possessing stoichiometrically equivalent amounts 
of an α subunit, which was determined to contain biotin, and a smaller β subunit [1]. In humans, 
plants, and bacteria, MCC primarily functions in leucine metabolism (Figure 1). 
 
Figure 1. Leucine metabolism in humans. A set of six reactions converts L-leucine into either 
energy metabolites (acetoacetate and acetyl-CoA) or mevalonate, which is a steroid precursor. The 
substances indicated in brackets on the right-hand side are metabolites that can accumulate when 
there is a deficiency in the function of their associated enzymes. Such accumulation can lead to 
their toxic buildup and subsequent consequences to human health. Adapted from [2]. 
 72 
MCC has been extensively researched for several decades, and its early characterization 
as a biotin-containing enzyme led to the identification of biotin as a common enzymatic cofactor 
[3]. MCC’s involvement in leucine metabolism was originally studied in Pseudomonas 
organisms, where it was discovered that MCC expression could be induced by growing 
Pseudomonas aeruginosa with leucine as its sole source of carbon and energy [4]. (Before the 
advent of recombinant cloning technologies, this approach constituted the most reliable method 
to obtain large amounts of the enzyme for biochemical studies.)  
Plant MCCs are also heteromeric complexes consisting of α and β subunits. The genome 
of Arabidopsis thaliana contains two MCC genes, each encoding for one subunit. Interestingly, 
in other plant species, as many as four genes are required to encode for a functional MCC 
subunit [5].  
 In humans, deficits in MCC expression or function can result in severe health issues due 
to the toxic buildup of unprocessed metabolites. Patients with such deficiencies are diagnosed 
with methylcrotonylglycinuria, and may present with vomiting, lethargy, and in severe cases, 
may experience seizures and developmental delays [6]. Methylcrotonylglycinuria is very similar 
to propionic acidemia (Chapter II) in that it is also inherited in an autosomal recessive fashion, 
has a relatively high incidence rate (1:50,000 individuals worldwide [7]), and spans a wide 
variety of phenotypes. Some individuals may exhibit acute symptoms at birth, while less-severe 
forms of the disease may go unnoticed or attributed to other maladies. Because MCC is directly 
involved in leucine metabolism, the majority of symptoms can be reduced by avoiding this 
amino acid, usually through a low-protein diet.  In some patients, the administration of 
supplemental biotin has been shown to help as well [8, 9]. A number of mutations in the human 
MCCA and MCCB genes (which code for the α and β subunits of MCC, respectively) have been 
 73 
identified, although additional structural and biochemical data are necessary to understand their 
consequences on the enzyme itself. 
Our interest in MCC stemmed directly from our studies of PCC and other biotin-
dependent carboxylases. Throughout our research, one question kept resurfacing: how does each 
enzyme maintain its particular substrate preferences when its constituent domains are so similar 
to those of the other enzymes? We decided to approach this question by comparing the β 
subunits of MCC and PCC, which both recognize acyl-CoA substrates in their CT active sites. 
In studying MCCβ, we hypothesized that it would exhibit a very similar structure to the 
PCCβ hexamer. From our investigations of PCC, coupled with the knowledge that MCC exhibits 
many similarities to PCC (including high sequence similarity, choice of acyl-CoA substrates, 
mitochondrial localization, and disease hallmarks), we predicted that “MCC is a close homolog 
of PCC … therefore, the PCC structure is directly relevant for MCC” [10]. Therefore, we 
focused on the architecture of the CT active site within MCCβ, and we hoped to determine the 
molecular features that allowed MCC (and not PCC) to (1) recognize a larger substrate and (2) 
carboxylate a different carbon on the substrate. 
 
 
3.2 Experimental Procedures 
 
Protein purification and mutagenesis 
Samples of Pseudomonas aeruginosa PAO1 were donated from Dr. Alice Prince 
(Columbia University) and the genomic DNA was isolated using established procedures [11]. 
The α subunit of MCC (PaMCCα) was cloned with a C-terminal hexahistidine tag in pET-26b 
and the β subunit (PaMCCβ) was cloned with an N-terminal hexahistidine tag in pET-28a. All 
cloning vectors were obtained from Novagen. The MCC holoenzyme (PaMCC) was generated as 
 74 
a bicistronic expression construct in pET-28a, and the final sequence of the construct was RBS-
(His)6-[PaMCCβ]-RBS-[PaMCCα], with “RBS” indicating a ribosomal binding site. The 
expression and purification schemes are identical to those described for PCC in Chapter II. All 
purified protein samples were concentrated to 20 mg/mL, flash-frozen in liquid nitrogen, stored 
at -80°C and thawed on ice for subsequent experiments. Biotinylation of the α subunit of MCC 
was confirmed using an avidin gel-shift assay. The N-terminal hexahistidine tags were not 
removed prior to crystallization.  
All point mutations were generated with the QuikChange kit (Agilent) and were 
sequenced to confirm the presence of mutations. The expression and purification schemes for the 
mutants were the same as those described for the wild-type enzyme. 
 
Kinetic studies of MCC 
The catalytic activity of MCC was measured using a coupled enzyme assay, which links 
the consumption of ATP by the BC domain to the disappearance of NADH [12]. The reaction 
buffer contained 100 mM HEPES-KOH (pH 8.0), 0.5 mM ATP, 8 mM MgCl2, 40 mM KHCO3, 
0.2 mM NADH, 0.5 mM phosphoenolpyruvate, 7 U lactate dehydrogenase, 4.2 U pyruvate 
kinase, 200 mM KCl, and 0.5 mM of either methylcrotonyl-CoA, crotonyl-CoA, or propionyl-
CoA. All reagents were obtained from Sigma. The reaction was initiated by adding 2 µg of 
protein to 100 µL of reaction buffer, and the progress was monitored by tracking the UV 





Crystallization of MCC  
Prior to setting up crystallization trays, the purified proteins were incubated with 2 mM 
methylcrotonyl-CoA on ice for 30 minutes. Initial crystallization conditions were identified using 
commercial sparse-matrix and grid screens (Emerald BioSystems, Hampton Research, Qiagen) 
and confirmed hits were optimized using the microbatch method under paraffin oil (Hampton 
Research) at 20°C. Crystals were produced by combining the purified protein (at 20 mg/mL) 
with precipitant solution in a 1:1 drop ratio. Cryoprotection was ensured by immersing the 
crystals in their respective precipitant solution, supplemented with glycerol for a final PEG + 
glycerol concentration of 35%. The cryoprotected crystals were then flash-frozen and stored in 
liquid nitrogen until data collection. 
The precipitant solution for PaMCCβ contained 0.1M MES (pH 6.5) and 1.6M MgSO4. 
After ten to fourteen days, cubic crystals approximately 0.3 mm3 in size were obtained (Figure 
2A), belonged to the R32 space group, and diffracted X-rays strongly (<2.0 Å resolution).  
The precipitant solution for the PaMCC holoenzyme contained either 0.2 M Na-malonate 
or 0.2 M Na2SO4, in addition to 20% (w/v) PEG-3350. After approximately two weeks, thin 
plates approximately 0.45 mm in length were observed (Figure 2B) and belonged to the P21 
space group. The majority of these crystals exhibited weak X-ray diffraction, and extensive 
screening was required to identify crystals suitable for data collection. CoA was observed in the 
active site of the β subunit upon elucidation of the final holoenzyme crystal structure. 
The conditions for the PaMCC+CoA crystals also produced crystals of the PaMCC free 
enzyme. After approximately six weeks at 20°C, the drops of protein and precipitant solution 
were significantly dehydrated, and the thin plates previously observed were replaced by highly 
birefringent block-shaped crystals, approximately 0.2 mm in length (Figure 2C). These crystals 
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exhibited significantly stronger X-ray diffraction, belonged to the R32 space group, and did not 
contain bound CoA in the final structure.  
 
 
Figure 2. Crystals of the β subunit and holoenzymes of MCC from Pseudomonas aeruginosa.  
(A) Crystals of full-length MCCβ free enzyme. (B) Crystals of full-length MCC complexed with 
CoA. (C) Crystals of full-length MCC free enzyme. The crystals in (C) were obtained from the 
same conditions as (B), but required substantially more time to grow. 
 
 
 In addition, three separate MCC mutants were generated by introducing the following 
point mutations into the β subunit: V375F, A218T, and a VF/AT double mutant. The 
crystallization conditions for these three mutants were the same as those for the wild-type MCC 
holoenzyme, with the exception that the double mutant also required the addition of 3.5% (w/v) 
benzamidine-HCl to the precipitant solution.  
 
Data collection and structure determination 
 
X-ray diffraction data were collected at 100 K, at the X29A beamline of the National 
Synchrotron Light Source (NSLS) at Brookhaven National Laboratory. All diffraction images 
were processed and scaled with HKL-2000 [13].  
For PaMCCβ, an X-ray diffraction data set was collected at 1.5-Å resolution, and the 
crystal belonged to the R32 space group, with cell parameters of a = b = 192.4 Å, c = 136.8 Å, α 
= β = 90.0°, and γ = 120.0°. The asymmetric unit contained a single β subunit. The structure was 
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solved with the molecular replacement program Phaser [14], using the structure of the β subunit 
of PCC [10] as the search model. The atomic model was built into the electron density map using 
O [15] and Coot [16], and the structure was refined using CNS [17] and Refmac [18] prior to 
deposition in the Protein Data Bank (accession code: 3U9R). 
For the CoA complex of the PaMCC holoenzyme, an X-ray diffraction data set was 
collected at 3.5-Å resolution, and the crystal belonged to the P21 space group, with cell 
parameters of a = 131.5 Å, b = 255.3 Å, c = 152.7 Å, α = 90°, β = 95.7°, and γ = 90°. There was 
one α6β6 dodecamer in the asymmetric unit. The structure was solved using Phaser for molecular 
replacement, and the structures of PaMCCβ and the BC domain of PCC [10] were used as search 
models. The BCCP domain of PCC was also used as a search model, but only one copy was 
found in the PaMCC structure. The structure of the BT domain was built into the electron density 
after structural refinement with CNS.  
For the PaMCC free enzyme, an X-ray diffraction data set was collected at 2.9-Å 
resolution, and the crystal belonged to the R32 space group, with cell parameters of a = b = 158.9 
Å, c = 312.0 Å, α = β = 90.0°, and γ = 120.0°. The asymmetric unit contained a single α-β 
protomer, and the structure was determined by molecular replacement with Phaser, using one α-β 
protomer from the PaMCC+CoA complex structure as the search model.  







Table 1. Crystallographic data and refinement statistics 
 






PDB accession code 3U9R 3U9S 3U9T 
Crystal data    
     Space group R32 P21 R32 
     Unit cell dimensions a=b=192.4 Å, 
c=136.8 Å,  
α=β=90°,  







c=312.0 Å,  
α=β=90°, γ=120° 
Diffraction dataa    
     Wavelength (Å)  1.075 Å   1.075 Å   1.075 Å  
     Resolution range (Å) 30–1.5 50–3.5 50-2.9 
     Redundancy  3.4 (2.6) 3.1 (2.4) 3.6 (3.4) 
     Completeness (%) 92 (73) 83 (61) 93 (82) 
     <I/σI> 10.8 (2.3) 8.3 (1.7) 16.0 (2.4) 
     Rmerge (%) 8.9 (35.9) 12.0 (45.1) 5.8 (38.8) 
Structure refinement    
     # of reflections used 141,517 104,480 31,522 






     RMSD bond lengths (Å) 0.017 0.014 0.011 
     RMSD bond angles (°) 1.7 1.8 1.7 
aValues in parentheses refer to the highest-resolution shell. 
bRfree = free R factor, based on a random sample of 5% of reflections.  
 
 
Electron microscopy (EM) studies 
All EM studies were performed by our collaborators in the laboratory of Dr. Z. Hong 
Zhou at the University of California, Los Angeles. Dilutions of the PaMCC holoenzyme were 
prepared in a buffer containing 25 mM Tris-HCl (pH 7.4) and 250 mM NaCl. For the negative 
stain experiments, 2.5 µL aliquots of diluted sample were spotted onto carbon-film-coated, glow-
discharged, 300-mesh copper grids, and excess sample was blotted away after 1 min. The sample 
was stained with a solution of 2% uranyl acetate and air-dried. One sample of optimal particle 
concentration was used for subsequent imaging and three-dimensional reconstruction analysis. 
The electron micrographs were obtained using a FEI TF20 electron microscope, and the images 
were recorded on a TVIPS 16MP CCD camera at 70,000X magnification. Approximately 20,500 
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particles were picked, using manual and automatic methods, during three-dimensional 
reconstruction. Another 12,000 particles were used for the final reconstruction.  
 
3.3 Initial investigations of MCC 
 The first investigations of MCC in our laboratory were conducted by Yang Shen, a 
graduate student and subsequent postdoctoral fellow in the lab. His studies of the α subunit from 
human MCC were intended to examine catalysis in the BC domain, in comparison to its fungal 
and bacterial ACC counterparts. However, the α subunits of human MCC were neither soluble 
nor inducible, and further studies were not performed.  
I began examining the molecular basis of substrate recognition in MCC by generating 
and screening through a collection of full-length bacterial MCCβ subunits with high sequence 
identity to human MCC (Table 2). The β subunit alone was targeted because the recognition and 
binding of the acyl-CoA substrate occurs entirely within this subunit, in a manner similar to 
PCC. In addition, although human MCC would have proven an ideal target, Chu et al. described 
the purification of human MCC holoenzyme as a demanding process, involving baculovirus 
expression and extremely low yields (36 µg protein per liter of insect cell culture), with the latter 
aspect being undesirable for crystallization trials [1]. Our success in determining the PCC 







Table 2. Bacterial MCCβ constructs 
 
# ID Organism Vector % Identity 
to human  
1 Pa Pseudomonas aeruginosa PAO1 pET-28a 65% 
2 Pf Pseudomonas fluorescens Pf-5 pET-28a 67% 
3 Re Rhizobium etli CFN42 pET-28a 64% 
4 Rpa Rhodopseudomonas palustris CGA009 pET-28a 63% 
5 Rr Rhizobium radiobacter C58 pET-28a 71% 
6 Rs Rhodobacter sphaeroides 2.4.1 pET-28a 66% 
7 Rp Ruegeria pomeroyi DSS-3 pET-28a 66% 




The best candidate from the screen of bacterial MCC β subunits was obtained from 
Pseudomonas aeruginosa PAO1, a Gram-negative bacterium and a well-known opportunistic 
human pathogen. Its β subunit (PaMCCβ) shares 65% sequence identity with the human 
homolog. PaMCCβ was purified to homogeneity and produced large rhomboid crystals (Figure 
2A) that diffracted to 1.5-Å resolution, and the structure was solved by molecular replacement. 
With this high-quality crystal structure, we began our investigations of the determinants of 
substrate preference in MCC. 
 
3.4 Structure of the 360-kDa β6 hexamer of 3-methylcrotronyl-CoA carboxylase  
 Upon first glance, the structure of PaMCCβ is remarkably similar to that of PCCβ (Figure 
3). Both are hexameric rings approximately 360 kDa in size, and both possess 32 symmetry. 
Each hexamer is a trimeric assembly of dimers, and the substrate-binding sites are formed at the 




Figure 3. Crystal structures of the β subunits of P. aeruginosa MCC (left) and Roseobacter 
denitrificans PCC (right). Both subunits assemble as hexamers, and the structures are viewed 
from the top face of each hexamer. The N domain of each β subunit is colored in cyan, and the C 
domain is colored in yellow. The arrows designate the direction (N’C’) of the linker that 
connects the two domains within each enzyme. For clarity, the protomer in the bottom layer under 




 However, much to our surprise, the structure of an individual β subunit was significantly 
different between MCC and PCC. The dashed lines in Figure 3 delineate the subunit boundaries 
within the hexamer, and demonstrate that there is a ‘swap’ of the N and C domains within each 
MCCβ subunit as compared to the domain arrangement in PCCβ. This finding was entirely 
unanticipated and was not predicted from sequence analysis; in fact, there is a shared sequence 
identity of 33% for the β subunits of MCC and PCC. Given this unexpected result, it was of 
considerable interest to investigate the origins of the domain swap and its potential consequences 





3.4.1 A unique domain arrangement for the β subunit of MCC   
 The N and C domains of the two enzymes are very similar in their overall appearance. 
Each domain contains a backbone crotonase fold, which consists of two perpendicular beta-
sheets linked by alpha-helices [19]. However, this similarity in appearance does not extend to the 
primary sequences. In other words, the N domain of MCCβ shares a higher sequence identity 
with the N domain of PCCβ than it does with the C domain of PCCβ. The same logic applies for 
the corresponding C domains of MCCβ and PCCβ. Therefore, the domain swapping is not a 
consequence of an internal gene rearrangement within the primary sequences of the β subunits.  
 
Figure 4.  A flexible 25-residue linker connects the N and C domains of β subunits from acyl-
CoA carboxylases. Omit Fo-Fc electron density map at 1.5-Å resolution for the domain linker of 




Figure 5.  Sequence alignment of various carboxyltransferase (CT) domains. The sequences 
of β subunits from various acyl-CoA carboxylases and the α subunit of glutaconyl-CoA 
decarboxylase (GCDα), which also recognizes an acyl-CoA substrate, are shown. The linker 
region is not well conserved among the enzymes. 
 
 
 Instead, the domain swap is a result of a connectivity difference between the N and C 
domains. A 60° rotation of either hexamer around its threefold axis places the N and C domains 
at equivalent positions to those of the other hexamer. However, the connection between the 
domains runs in opposite directions, and is thusly indicated by the arrows in Figure 3. In our 
structure, the electron density for the linker in PaMCCβ is clearly defined at 1.5-Å resolution 
(Figure 4). This linker is present in all the acyl-CoA-recognizing subunits of biotin-dependent 
carboxylases (Figure 5). Although the length of the linker is essentially constant between the 
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enzymes, its sequences are not highly conserved. This suggests that the linker is not well-
structured and functions as a simple and flexible connection between the two domains.  
 One explanation for the ‘swapped’ domains in PaMCCβ is the presence of a long (25-
residue) helix at the N-terminal end of the N domain (Figure 3). This helix falls across the outer 
edge of the corresponding C domain, and may be involved in stabilizing the unique domain 
connectivity in MCCβ. In our structure of PaMCCβ, there are several points of close contact that 
can be attributed to hydrophobic and van der Waals interactions. There are no ion pairs observed 
between the N-terminal helix and the C domain.  
 One approach to assessing the role of the N-terminal helix is to generate a series of 
truncation mutants within the motif, and observe the effects of the mutations on the structure of 
the MCCβ hexamer. If a mutant assumes the domain organization of PCCβ, then the helix can be 
assumed to possess stabilizing interactions with the C domain. To date, two mutants have been 
made: the M22 mutant is missing the N-terminal one-third of the helix, and the N27 mutant is 
missing the N-terminal half. Both mutants were expressed in the insoluble fraction of the E. coli 
cell lysate, preventing further studies. This suggests that while the helix has not yet been 
implicated in the domain swap, its presence is essential to allow for proper folding and assembly 
of the PaMCCβ subunits. 
 
3.4.2 Consequences of the domain swap on the CT active site  
 The initial incentive for studying MCCβ was to identify the molecular basis for substrate 
recognition, and how the elements governing its substrate preferences compared to those of 
PCCβ. (For reference, the structures of 3-methylcrotonyl-CoA and propionyl-CoA are shown in 
Chapter II.) Our efforts to produce a co-crystal of MCCβ in complex with its native substrate 
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were unsuccessful; therefore, we prepared a model of the PaMCC β2 dimer with the bound 
positions of crotonyl-CoA from the alpha subunit of Clostridium symbiosum glutaconyl-CoA 
decarboxylase (GCDα) [20], as shown in Figure 6. GCDα shares 26% sequence identity with 
PaMCCβ and also features the same domain connectivity. (The binding of glutaconyl-CoA to 
GCDα is the first step of the decarboxylation reaction, and for this reason it is referred to as the α 
subunit of the holoenzyme. The biotin-dependent carboxylases bind acyl-CoA substrates during 
the 2nd reaction, and their β subunits are named accordingly.)  
 
Figure 6. Schematic representations of β2 dimers from MCC (left) and PCC (right). The 
MCC β2 dimer is shown with the bound positions of crotonyl-CoA in complex with the α subunit 
of glutaconyl-CoA decarboxylase (GCDα) [20], and the PCC β2 dimer is shown in complex with 




The resulting structural model revealed another consequence of the N/C domain swap, 
which was a swap in the positions of the CoA binding sites between MCCβ and PCCβ. Although 
the active sites are still formed at the interface of N and C domains from opposing protomers, 
their overall positions within the hexamer are different. From a biochemical perspective, this 
active-site rearrangement does not have significant consequences on catalysis, as MCC holds 
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important roles in intermediary metabolism and its robust activity has been extensively 
documented in many species. Therefore, MCC’s functional activity is not compromised because 
of its unique β-subunit organization.  
From a structural perspective, however, there is a strong possibility that the active-site 
swap precludes the MCC holoenzyme from possessing the same overall architecture as PCC. The 
rationale for this lies in the precise architecture of the catalytic components, and their co-
evolution over time. In other words, the BCCP domain of PCC has evolved to ‘expect’ the CT 
active site at a specific location within the β6 hexamer. The structure of the PCC holoenzyme 
shows six BCCP domains, all bound in identical conformations to the CT active site of the 
nearest PCCβ protomer. If the CT active site is moved to MCC’s location (which is related to 
PCC by a 60° rotation around the ring), the configuration of PCC’s BC/BCCP is unlikely to 
‘find’ the new location, unless the positions of the BC/BCCP are moved as well. To investigate 
this hypothesis, a crystal structure of the MCC holoenzyme was pursued. 
 
3.5 Structure of the 750-kDa α6β6 holoenzyme of 3-methylcrotonyl-CoA carboxylase 
 The MCC holoenzyme from Pseudomonas aeruginosa (PaMCC) was produced as a 
bicistronic expression construct, similar to the PCC holoenzyme (Chapter II). The enzyme was 
readily purified and produced thin plate-shaped crystals. One crystal produced a data set 
diffracting to 3.5-Å resolution, and the resulting structure is shown in Figure 7. 
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Figure 7. Structure of the MCC holoenzyme. (A) A view looking down the threefold symmetry 
axis of P. aeruginosa 3-methylcrotonyl-CoA carboxylase [22]. (B) A view looking down the 
twofold symmetry axis. The gray envelopes in (C) and (D) are cryo-EM reconstructions of 
PaMCC contoured at 12-Å resolution, with the crystal structure of the holoenzyme docked within, 
and the views are presented in the same orientations as (A) and (B). The crystal structure figures 
were produced with PyMOL [23] and the cryo-EM figures were generated in Chimera [24]. 
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 Like PCC, the structure of the PaMCC holoenzyme is an α6β6 dodecamer, 750 kDa in 
size, displays 32 symmetry, and also assumes a cylindrical shape. The β6 hexamer comprises the 
central core, and the subunit architecture also follows an α3β3β3α3 arrangement. Only a single 
ordered BCCP was observed in the structure of PaMCC complexed with CoA, and the domain is 
disordered in the PaMCC free-enzyme structure.  
 
Figure 8. CoA binding induces minor conformational changes in the structure of the MCC 
holoenzyme. The holoenzyme structures of the MCC free enzyme (gray) and CoA complex 
(color) are superimposed at the level of the β6 hexamer. Differences in the two structures are 
evident in the positions of the B domain of BC, the α6/α6A helices in the β subunit, as well as the 
absence of BCCP in the free-enzyme structure. 
 
The binding of CoA does not have significant effects on the overall architecture of the 
MCC holoenzyme. There is, however, a minor (~6°) rotational difference in the positions of the 
α subunits with respect to the crystallographic threefold axis, upon CoA binding (Figure 8). In 
addition, the free-enzyme structure exhibits a few sites with disordered segments, including the 
α6-α6A extensions of the β subunit’s C domain (viewed as the yellow and green protrusions 
from the hexamer) and within the distal B domain of the BC subunit (viewed as the unconnected 
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red and magenta strands in Figures 7B and 7D). In general, however, the structures of the CoA 
complex and the free enzyme are very similar, and may represent transitional stages within the 
overall MCC reaction. The subsequent MCC holoenzyme structures shown in this Chapter are of 
the CoA complex (3U9S) unless otherwise noted.  
 Our collaborators in the laboratory of Dr. Z. Hong Zhou (UCLA) also produced a cryo-
electron microscopy (cryo-EM) reconstruction of PaMCC at 12-Å resolution, and the crystal 
structure docks very well into the cryo-EM envelope (Figures 7C and 7D). The cryo-EM 
structures do not show the BCCP domain, which may be due to the domain’s inherent flexibility. 
The excellent agreement between the structures indicates that MCC maintains the same 
conformation in both the solution state and within the protein crystal.  
 
 
Figure 9. Comparing the MCC and PCC holoenzymes. The crystal structures of the MCC and 
PCC holoenzymes are rendered as molecular surfaces, and equivalent domains are colored in 
similar tones. Only one BCCP was identified in the structure of PaMCC. Although the two 
enzymes are very similar in terms of sequence conservation, domain organization, and function, 
their three-dimensional structures are distinct from each other. 
 
 Although there are a number of structural similarities shared by the MCC and PCC 
holoenzymes, their overall three-dimensional architectures are very different (Figure 9).  
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The arrangement of α subunits around the hexameric core is entirely unique between the 
two enzymes. While the α subunits of PCC are monomeric and are splayed far apart from each 
other, the α subunits of MCC form a single trimeric unit at the top and bottom of the holoenzyme 
structure. The forces maintaining the trimeric association are relatively weak in nature; 
biochemical investigations of MCCα show that it does not form a stable oligomeric complex in 
solution, and the results of size-exclusion chromatography indicate that the size of the purified 
protein is equivalent to that of a single α monomer (unpublished studies).  
In the MCC holoenzyme structure, the BC/BT domains essentially sit atop the N-domain 
of the underlying β subunit. A single BCCP domain was observed in the holoenzyme structure, 
and also binds a CT active site. Interestingly, the binding mode of this BCCP is nearly identical 
to the one observed in PCC – but because of the swapping of the positions of the N- and C-
domains, the BCCP in MCC contacts a different β2 dimer than the one above which its BC/BT 
domains are located. Therefore, a single round of catalysis in MCC involves one α subunit and 
two β2 dimers (one to form the ‘foundation’ under the BC/BT domains and another to form the 
CT active site). In PCC, a corresponding round of catalysis involves one α subunit and one β2 
dimer, because this dimer provides both the ‘foundation’ and CT active site. Therefore, an α2β2 
tetramer of PCC is probably catalytically active, while such a version of MCC is not. 
The dimensions of the MCC holoenzyme are also elongated with respect to PCC; the 
formation of the α-subunit trimers extends the length of the MCC holoenzyme to approximately 
210 Å, while the vertical dimension of PCC measures approximately 160 Å. The size of the β6 
hexamer is unchanged between the two structures, with a diameter of approximately 140 Å. In 
addition, although the active sites of MCCβ are located in different positions than those of PCCβ, 
both holoenzyme structures feature at least one BCCP bound to the CT active site. Finally, the 
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structure of the MCC holoenzyme also reveals the presence of a BT domain, which was first 
identified in our structure of PCC (Chapter II).  
 
3.5.1 The BT domain of MCC 
 
 MCC also features a BT domain for mediating BC-CT interactions, and its overall fold 
resembles a short α-helix surrounded by a highly curved, 7-stranded β-sheet (Figures 10A-B). 
The BT domain of PCC, in contrast, features a long helix surrounded by an 8-stranded β-barrel 
(Figure 10C). Both BT domains possess a distal ‘hook’ that anchors the α subunits into the β 
hexamer, although the conformation of MCC’s hook is quite different from that of PCC. 
 
Figure 10. The BT domain. (A) Location of the BT domain within the MCC holoenzyme. The 
sites of four ‘hook’ residues proposed to contribute to holoenzyme integrity are indicated with 
spheres. (B) Schematic representation of the BT domain from MCC. (C) Schematic representation 
of the BT domain from PCC. 
 
Of the approximately 3,000 Å2 of buried surface area between each α subunit and the β6 
hexamer, approximately 55% of the interactions are mediated by the BT domain. The BCCP 
domain, when bound to the active site of the β subunit, contributes approximately 23% of the 
interactions (as measured by the amount of buried surface area between the two domains). 
Interestingly, there is no direct contact between the BC domain and the β6 hexamer in the 
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structure of the MCC holoenzyme (the two are separated by 18 Å), which is very different from 
the BC domains in PCC. 
The ‘hook’ feature in BT interacts with both the N and C domains of the β subunit, and 
the conformations of its component side chains appear to make several ion-pair interactions with 
the side chains from the β6 hexamer. In order to understand the contribution of these ‘hook’ 
residues to BT’s function in maintaining α-β association, a series of non-conservative mutations 
were generated at the sites of selected residues, and the resulting effects on holoenzyme stability 
were measured by a pull-down experiment. (In the MCC holoenzyme construct, only the β 
subunit carries the hexahistidine tag. If the α subunits associate with the β hexamer to form an 
intact holoenzyme, the entire α6β6 complex can be isolated using the β-His6 tags. If the α subunits 
fail to bind the β subunits, then only the β subunits alone will be purified by nickel-affinity 
chromatography.) 
 
Figure 11. Mutations in the BT hook structure can destabilize the MCC holoenzyme. Lane 
headings indicate P for the E. coli cell pellet, S for the supernatant fraction, and E for the eluted 




The results of the pull-down experiment implicate Ser535, Phe537, Arg543, and Arg 544 
in maintaining the integrity of the MCC holoenzyme. Figure 11 demonstrates that the levels of α-
subunits co-eluted with MCCβ are significantly reduced compared to the wild-type levels, which 
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represent the stoichiometric ratios of α to β subunits in native MCC. From a functional 
perspective, any of these mutations can severely inhibit MCC holoenzyme integrity, and in turn, 
MCC’s catalytic activity.  
 
3.5.2 The carboxyltransferase active site  
 
 The structure of PaMCC lent considerable insight into the consequences of the domain 
swap on the active site locations, and revealed that the active sites of the α and β subunits are 
separated by 80 Å, which to date is the largest distance between the two active sites of a biotin-
dependent carboxylase. More important, Figure 12 reveals that for a given α subunit, its BT 
domain primarily contacts the closest β subunit, but its BCCP domain accesses the active site of 




Figure 12. The BC and CT active sites of MCC. Stereo view of one α subunit and the β6 
hexamer. The BCCP domain (in blue) must translocate a considerable distance to access the two 
active sites. The hexamer is viewed from the side, in the same manner as Figure 6. 
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However, the effects of the active site swap on communication between the α and β 
subunits was not clear. In particular, it was not known how BCCP recognizes the CT active site 
in the context of a novel MCC architecture. A detailed look at the architecture of the CT active 





Figure 13. The CT active site. (left) The substrate-binding pocket is buried deep in the groove 
formed by the N and C domains of different β subunits. The overlaying portions of the C domain 
are rendered partially transparent to reveal the positions of biotin and 3-methylcrotonyl-CoA 
(MCoA). (right) Detailed view of the CT binding site. Helix α6 is rendered partially transparent to 
show the MCoA. Although CoA was observed in the MCC holoenzyme structure, the additional 
acyl groups were modeled using the binding mode of crotonyl-CoA in complex with GCDα [20]. 
 
 
 Compared to PCC, the positions of biotin and 3-methylcrotonyl-CoA are buried much 
deeper within the CT active site of MCC. There is a shift in the positions of the α6 and α6A 
helices, such that they form a makeshift lid over the active site. In addition, several other 
conformational shifts are observed in the vicinity of 3-methylcrotonyl-CoA’s acyl group, which 
is consistent with the hypothesis that a larger substrate necessitates a larger binding pocket. The 
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γ-carbon of 3-methylcrotonyl-CoA, which is the target of MCC carboxylation, is located 
approximately 6 Å away from the N1' atom of biotin. This distance is sufficient to place the γ-
carbon within reach of carboxybiotin and allow for catalysis. The binding mode of biotin in the 
structure of PCC reveals that its biotin N1' atom is not buried as deeply within the active site, and 
therefore, PCC is unlikely to accommodate 3-methylcrotonyl-CoA as a substrate.  
 
3.6 Effects of disease-causing mutations  
 The elucidation of the MCC holoenzyme structure provides a framework on which to 
study the molecular consequences of disease-associated gene mutations. Depending on the 
location of the mutations, their effects may range from reduced catalytic efficiency to disruption 
of the holoenzyme structure. There are approximately three dozen missense mutations in human 
MCC that have been identified and found to correlate with the genetic disease 
methylcrotonylglycinuria. These mutations have been mapped to the structure of PaMCC (Figure 
14). For the most part, the residues that are implicated in humans are also conserved in P. 
aeruginosa, which may testify to their importance for proper MCC activity.  
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Figure 14. Locations of the BC and CT active sites and disease-associated gene mutations in 
the MCC holoenzyme. (A) Schematic representation of one α subunit and a β2 dimer with the 
bound positions of ADP from E. coli ACC [26] and CoA. The locations of missense mutations 
associated with the human disease methylcrotonylglycinuria are indicated with spheres. Panels (B) 
and (C) depict the consequences of the E134K mutation in the BC domain, and (D) and (E) 
indicate likewise for the V375F mutation in the CT domain. 
 
 One example of a mutant potentially disrupting BC catalysis is E134K. Based on the 
structure of E. coli BC in complex with ADP, biotin, bicarbonate, and Mg2+ [26], a catalytic 
scheme for BC was proposed. In this mechanism, Arg292 was hypothesized to stabilize the 
bicarbonate ion (the source of CO2 for the overall carboxylation reaction) prior to catalysis. 
Arg292, in turn, is held in a stable conformation by Glu87, and their proposed ion-pair 
interaction is 3 Å in length. Based on sequence and structural alignments, the corresponding 
residues in PaMCC are Arg339 and Glu134. Figures 14B and 14C illustrate the potential 
consequences of an E134K mutation. The replacement of Glu134 by a positively charged lysine 
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residue eliminates the ion-pairing that stabilizes Arg339, and by extension, bicarbonate. As a 
result, the bicarbonate ion loses a major stabilizing force in its pre-catalytic positioning, and the 
overall catalytic efficiency is likely reduced. 
 Within the CT domain, the V375F mutation (Figures 14D-E) does not disturb 
electrostatic interactions. Rather, the introduction of a bulky phenylalanine side chain is thought 
to introduce steric clashes with the side chains of BCCP. This may compromise the ability of 
BCCP-biotin to access the CT active site, thus affecting catalysis. Val375 is well conserved 
among the β subunits of various MCCs, and the V375F mutation has been found to correlate 
with methylcrotonylglycinuria in several patients. By engineering the V375F mutation into 
PaMCC, it is possible to observe whether catalysis is affected, and a structural model may reveal 
an alternative placement for BCCP if it cannot access the CT binding site. Additional discussion 
of this mutation is presented in the following section. 
 It is important to note that there is a wide spectrum of phenotypes associated with 
methylcrotonylglycinuria, even among patients with apparently identical disease mutations. As 
such, clinical data have not demonstrated a clear genotype-phenotype correlation for MCC 
deficiency [27, 28]. Nonetheless, the structures of MCC and related holoenzymes still provide a 
valuable foundation for studying the relationships between disease mutations and their resulting 
effects on enzymatic stability and/or function, and offer the possibility of designing therapeutic 
approaches to counter the effects of methylcrotonylglycinuria and other metabolic disorders.  
 
3.7 Investigating BC-BCCP interactions 
 
In order to fully understand the two-part mechanism and the basis of BCCP translocation 
in biotin-dependent carboxylases, it is necessary to study the interactions of BCCP-biotin with 
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both the BC and CT active sites. To date, the majority of studies have observed BCCP binding 
the CT domain. In addition to PCC and MCC, the interactions of BCCP-biotin with the CT 
active sites of human and Rhizobium etli pyruvate carboxylase have also been described [29].  
In contrast, there are no documented reports of BCCP-biotin directly interacting with the 
BC active site. The current knowledge of BC catalysis stems from several crystal structures of 
the BC domain, either alone [30], in complex with ATP analogs [31], or in complex with biotin, 
bicarbonate, and Mg-ADP [26]. There have also been reports of BCCP interacting with the BC 
domain of R. etli PC [32] and E. coli ACC [33]. However, neither structure features BCCP 
bound within the BC active site. To address this lack of information regarding BC-BCCP 
interactions, we pursued a MCC mutation that would ‘coax’ the BCCP domain out of its current 
location in CT active site, and hopefully into the BC active site. 
 
3.7.1 Preliminary results for a BCCP ‘eviction mutant’ 
 
It is not known why BCCP possesses an apparent preference for the CT domain in the 
holoenzyme structures of PC, PCC, and MCC. After all, the mobile domain should exhibit 
similar affinities for the BC and CT active sites to promote efficient catalysis. Structural studies 
of the CT active site have identified a number of conserved non-covalent interactions that 
stabilize CT-BCCP binding. Mutations at these sites may destabilize BCCP from binding the CT 
domain – and upon its eviction from CT, BCCP may be favored to bind BC instead. 
Based on the structure of the MCC holoenzyme, two disease-causing mutations in the CT 
active site were identified as possible stabilizers of CT-BCCP binding. The side chain of Arg218 
(Figure 13) is located between 3-methylcrotonyl-CoA and the biotin group of BCCP, and the 
A218T mutant may prevent binding of one or both ligands. Val375 (Ile375 in PaMCC; Figure 
14) is situated at the interface of the N domain of MCCβ and BCCP, and the V375F mutant may 
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introduce steric clashes to prevent BCCP-biotin from accessing the CT active site. To assess the 
effects of these mutations on MCC catalysis and integrity, several ‘eviction mutants’ were 




Figure 15. Kinetic assay of wild-type MCC and BCCP eviction mutants. An ATP hydrolysis 
assay was used to compare the catalytic activities of three MCCβ mutants against wild-type MCC. 
Each curve represents the average of three separate trials. The activity of wild-type MCC was 
arbitrarily set to 1.0, and the activities of the mutants are calculated in comparison to this value. 
 
 
All three mutants were purified to homogeneity and their catalytic activities were 
surveyed using an ATP hydrolysis assay. Figure 15 shows that all three mutants exhibit 
significantly diminished catalysis compared to wild-type PaMCC. The A218T mutation proved 
more detrimental to MCC activity than the V375F mutation, and both A218T and the double 
mutant had equally low activities. With the reassurance that these mutations had significant 
effects on MCC catalysis, we decided to investigate the structural consequences of the mutations. 
In particular, we wanted to determine whether the reduced catalytic activities of the mutants 






Figure 16. Crystals of BCCP eviction mutants from PaMCC. Mutations were introduced in the 
MCCβ subunit, with the intention of destabilizing BCCP-biotin interactions. Crystallization 
conditions are summarized in the Experimental Procedures.  
 
 
Crystals of all three mutants were obtained using the same crystallization conditions as 
the wild-type MCC holoenzyme. The VF/AT double mutant crystals diffracted X-rays more 
strongly than the single mutant crystals. Currently, the best VF/AT crystal diffracts to 
approximately 5-Å resolution using a synchrotron radiation source, belongs to the C2221 space 
group, and was indexed with approximate unit cell parameters of a = 243 Å, b = 249 Å, c = 153 
Å, and α = β = γ = 90°. Efforts are underway to improve the quality of these crystals.  
 
3.7.2 Future perspectives 
  
 The primary goal for generating the VF/AT double mutant is that the BCCP domain will 
be destabilized from binding in the CT active site and will be evicted from this location. Ideally, 
the BC active site will also provide a series of non-covalent interactions to stabilize BCCP 
binding, and BCCP-biotin will be observed binding at the BC active site. Substrates of the BC 
reaction (Mg-ATP and bicarbonate) can also be added to the crystallization conditions to 
stabilize BCCP in the BC active site. Phosphonoacetate is a structural analog of 
carboxyphosphate (an intermediate of the BC reaction), and can also be used to capture BCCP-
biotin in BC and prevent its translocation to the CT domain. Additional crystal optimization may 
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also be required; the binding of BC-BCCP may induce a global conformational change in the 
entire holoenzyme, thereby affecting crystal packing. If current efforts to improve the crystals’ 
diffraction quality are not successful, then the purified VF/AT mutant will be re-tested against 
our collection of sparse-matrix and grid crystallization screens.  
Another potential finding from the VF/AT structure is that BCCP is evicted from the CT 
domain, but does not enter the BC active site, and instead, settles elsewhere on the holoenzyme. 
This outcome has been observed previously with the structure of S. aureus pyruvate carboxylase 
(in which BCCP is binds an exo site) [29] and R. etli pyruvate carboxylase (in which BCCP 
binds BC, but not within the active site) [32]. 
By determining the structure of BCCP-biotin bound in the BC active site, we hope to 
understand the basis of BC catalysis in the context of the holoenzyme. The residues that govern 
BCCP and biotin binding are of particular interest, as their interactions must be specific enough 
to align all the reaction substrates in place for catalysis, but also transient in nature, to allow for 
BCCP-carboxybiotin translocation to the CT active site. In addition, the structure of BCCP-
biotin bound to the BC active site will allow us to better understand the consequences of disease-
associated gene mutations on the activity and architecture of the BC domain, in addition to 
understanding how BCCP translocation may be used in regulating the activity of the 
holoenzyme. 
 
3.8 Implications of findings: two lineages of biotin-dependent acyl-CoA carboxylases 
 
 Our studies of the MCC represent the fourth reported crystal structure of a biotin-
dependent carboxylase holoenzyme, and the third such structure from our laboratory. The 
structure of PaMCCβ revealed a surprising domain swap of the N and C domains compared to 
PCCβ, and this finding was not apparent from primary sequence analysis. The overall 
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architecture of the MCC holoenzyme is different from PCC as well, especially in the trimeric 
association of its BC domains, its modified BT domain, and swapping of the CT active sites. 
Studies to further investigate the CT active site and the interactions of BCCP in the BC domain 
are currently underway.  
 The structural knowledge garnered by the MCC and PCC holoenzymes suggest that there 
may be two distinct lineages of biotin-dependent acyl-CoA carboxylases (Figure 17). One 
lineage targets the α-carbon of saturated acids, and includes ACC and PCC. The other lineage 
carboxylates the γ-carbon of α-β unsaturated acids, and includes MCC, GCC (geranyl-CoA 
carboxylase), and GCD (glutaconyl-CoA decarboxylase). The CoA substrates of GCC and GCD 
feature substantially larger acyl groups, and it is expected that their corresponding binding sites 
in the enzymes must accommodate the increased bulk by an expansion and/or rearrangement of 
the active site architecture.  
 
Figure 17. Two proposed lineages of acyl-CoA carboxylases. One lineage (orange) carboxylates 
the α-carbon of acyl-CoA substrates, while another targets the γ-carbon of the acyl-CoA. The sites 
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